Document:

EX-10.12

 Exhibit 10.12 

LINKDOC TECHNOLOGY LIMITED 

2021 Global Share Plan 

Section 1. Purpose. 

The purpose of the LinkDoc Technology Limited (“LinkDoc”) 2021 Global Share Plan (“2021 Global Share Plan”)
is to enhance the ability of LinkDoc to attract and retain exceptionally qualified individuals and to encourage them to acquire a proprietary interest in the growth and performance of the Company. 

Section 2. Structure. 

Each Award (as defined below) granted by the Company pursuant to the terms of this 2021 Global Share Plan, shall be granted to each
participant, and the corresponding Shares issuable upon the exercise of such Award (the “Award Shares”) shall be issued to the participants or an entity designated by the participants. 

Section 3. Definitions. 

As used in this 2021 Global Share Plan and any Award Agreement (as defined below), the following terms shall have the meanings set forth
below: 
 (a) “2021 Global Share Plan” shall mean this LinkDoc 2021 Global Share Plan, as amended from time
to time. 
 (b) “Affiliate” shall mean (i) any entity that, directly or indirectly, is controlled by
the Company and (ii) any entity in which the Company has a significant equity interest, in either case as determined by the Committee. 

(c) “Applicable Laws” shall mean all laws, statutes, regulations, ordinances, rules or governmental
requirements that are applicable to this 2021 Global Share Plan or any Award granted pursuant to this 2021 Global Share Plan, including but not limited to applicable laws of the People’s Republic of China (“PRC”), the United
States and the Cayman Islands, and the rules and requirements of any applicable securities exchange. 
 (d)
“Award” shall mean any Option, award of Restricted Share, Restricted Share Unit or Other Share-Based Award granted under this 2021 Global Share Plan. 

(e) “Award Agreement” shall mean any written agreement, contract or other instrument or document evidencing
any Award granted under this 2021 Global Share Plan. 
 (f) “Board” shall mean the board of directors of the
Company. 
 (g) “Cause” shall mean an act or acts on the part of the Participant constituting a violation of
the internal rules and procedures of the Company or an Affiliate that employs or retains such Participant. 
 (h)
“Committee” shall mean the Compensation Committee of the Board. In the absence of any compensation committee or any other related designation by the Board, the Board shall assume all of the powers and responsibilities under this
2021 Global Share Plan. 
 (i) “Company” shall mean LinkDoc Technology Limited, a company incorporated under
the laws of the Cayman Islands, together with any successor thereto. 
 (j) “Consultant” means any
individual, including an advisor, who is engaged by the Company or an Affiliate to render services and is compensated for such services, and any director of the Company whether or not compensated for such services. 

 (k) “Discharge” shall mean that the relationship between
the Participant and the Company or an Affiliate, whether it is employment or consultancy, is terminated due to economic layoffs or restructuring of the Company or an Affiliate, as the case may be. 

(l) “Fair Market Value” shall mean, with respect to any property (including, without limitation, any Shares or
other securities) the fair market value of such property determined by such methods or procedures as shall be established from time to time by the Committee. 

(m) “Option” shall mean an option granted under Section 7 hereof. 

(n) “Other Share-Based Award” shall mean a right granted under Section 9 hereof. 

(o) “Participant” shall mean an individual granted an Award under this 2021 Global Share Plan. 

(p) “Restricted Share” shall mean any Share granted under Section 8 hereof. 

(q) “Restricted Share Unit” shall mean a contractual right granted under Section 8 hereof that is
denominated in Shares, each of which represents a right to receive the value of a Share (or a percentage of such value, which percentage may be higher than 100%) upon the terms and conditions set forth in this 2021 Global Share Plan and the
applicable Award Agreement. 
 (r) “Shares” shall mean ordinary shares of the Company, par value $0.00008
per share. 
 (s) “Substitute Awards” shall mean Awards granted in assumption of, or in substitution for,
outstanding awards previously granted by, or held by the employees of, a company or other entity or business acquired (directly or indirectly) by the Company or with which the Company combines. 

Section 4. Eligibility. 

(a) Employees (each, an “Employee”) and the Consultants of the Company or an Affiliate are eligible to participate in this
2021 Global Share Plan. An Employee or Consultant who has been granted an Award may, if he or she is otherwise eligible, be granted additional Awards. 

(b) An individual who has agreed to accept employment by, or to provide services to, the Company or an Affiliate shall be deemed to be
eligible for Awards hereunder as of the date of such agreement. 
 Section 5. Administration. 

(a) This 2021 Global Share Plan shall be administered by the Committee formed in accordance with applicable stock exchange rules, unless
otherwise determined by the Board. The term “Administrator” shall refer to the Board or the Committee, as applicable. The Administrator may delegate its duties and powers under this 2021 Global Share Plan in whole or in part to a person or
committee designated by it. 
 (b) Subject to the terms of this 2021 Global Share Plan and Applicable Laws, the Committee shall have full
power and authority to: (i) designate Participants; (ii) determine the type or types of Awards (including Substitute Awards) to be granted to each Participant under this 2021 Global Share Plan; (iii) determine the number of Shares to
be covered by (or with respect to which payments, rights, or other matters are to be calculated in connection with) Awards; (iv) determine the terms and conditions of any Award; (v) determine whether, to what extent, and under what
circumstances Awards may be settled or exercised in cash, Shares, other securities, other Awards, or other property, or canceled, forfeited or suspended, and the method or methods by which Awards may be settled, exercised, canceled, forfeited or
suspended; (vi) determine whether, to what extent, and under what circumstances cash, Shares, other securities, other Awards, other property, and other amounts payable with respect to an Award under this 2021 Global Share Plan shall be deferred
either automatically or at the election of the holder thereof or of the Committee; (vii) interpret and administer this 2021 Global Share Plan and any instrument or agreement relating to, or Award made under, this 2021 Global Share Plan;
(viii) establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of this 2021 Global Share Plan; (ix) determine whether and to what extent Awards should
comply or continue to comply with any requirement of statute or regulation; and (x) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this 2021 Global Share Plan.

  
 2 

 (c) All decisions of the Committee shall be final, conclusive and binding upon all persons,
including the Company, the shareholders of the Company and the Participants and their beneficiaries. 
 Section 6. Shares Available
for Awards. 
 (a) Subject to adjustment as provided below, the maximum aggregate number of Shares that may be issued pursuant to all
Awards shall not exceed 30,000,000 Ordinary Shares. 
 (b) If, after the effective date of this 2021 Global Share Plan, any Shares covered
by an Award, or to which such an Award relates, are forfeited, cancelled or if such an Award otherwise terminates without the delivery of Shares or of other consideration, then the Shares covered by such Award, or to which such Award relates, to the
extent of any such forfeiture or termination, shall again be, or shall become, available for issuance under this 2021 Global Share Plan. 

(c) In the event that any Option or other Award granted hereunder (other than a Substitute Award) is exercised through the delivery of Shares,
or in the event that withholding tax liabilities arising from such Option or Award are satisfied by the withholding of Shares by the Company, the number of Shares available for Awards under this 2021 Global Share Plan shall be increased by the
number of Shares so surrendered or withheld. 
 (d) Any Shares delivered pursuant to an Award may consist, in whole or in part, of
authorized and unissued Shares, treasury Shares or Shares purchased on the open market. 
 (e) In the event that the Committee shall
determine that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Shares or other securities of the Company, issuance of warrants or other rights to purchase Shares or other securities
of the Company, or other similar corporate transaction or event affects the Shares such that an adjustment is determined by the Committee to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to
be made available under this 2021 Global Share Plan, then the Committee shall, in such manner as it may deem equitable, adjust any or all of (i) the number and type of Shares (or other securities or property) which thereafter may be made the
subject of Awards, including the aggregate limit specified in Section 6(a) hereof, (ii) the number and type of Shares (or other securities or property) subject to outstanding Awards, (iii) the grant, purchase, or exercise price with
respect to any Award or, if deemed appropriate, make provision for a cash payment to the holder of an outstanding Award, and (iv) the minimum number of Shares which may be purchased by the holder of an outstanding Award at any one
time; provided, however, that the number of Shares subject to any Award denominated in Shares shall always be a whole number. 

(f) Shares underlying Substitute Awards shall not reduce the number of Shares remaining available for issuance under this 2021 Global Share
Plan. 
 Section 7. Options. 

The Committee is hereby authorized to grant Options to Participants with the following terms and conditions and with such additional terms and
conditions, in either case not inconsistent with the provisions of this 2021 Global Share Plan, as the Committee shall determine and set forth in the Award Agreement: 

(a) The purchase price per Share, if any, under an Option shall be determined by the Committee. 

(b) The term of each Option shall be fixed by the Committee; provided, however, that the term shall not be
longer than ten years from the date of grant thereof. 

  
 3 

 (c) The Committee shall determine the time or times at which an Option may
be exercised in whole or in part, and the method or methods by which, and the form or forms, including, without limitation, cash, Shares, other Awards, or other property, or any combination thereof, having a Fair Market Value on the exercise date
equal to the relevant exercise price, in which, payment of the exercise price with respect thereto may be made or deemed to have been made. 

Section 8. Restricted Shares and Restricted Share Units. 

(a) The Committee is hereby authorized to grant Awards of Restricted Shares and Restricted Share Units to Participants. 

(b) If Restricted Shares are granted to or received by a Participant under an Award (including a Share Option), the Committee shall set forth
in the related Award Agreement: (i) the number of Shares awarded, (ii) the price, if any, to be paid by the Participant for such Restricted Shares, (iii) the time or times within which such Award may be subject to forfeiture, and
(iv) all other terms, limitations, restrictions, and conditions of the Restricted Shares, which shall be consistent with this Plan. 

(c) Restricted Shares and Restricted Share Units shall be subject to such restrictions as the Committee may impose (including, without
limitation, any limitation on the right to vote a Restricted Share or the right to receive any dividend or other right or property), which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise,
as the Committee may deem appropriate. 
 (d) Any Restricted Share granted under this 2021 Global Share Plan may be evidenced in such manner
as the Committee may deem appropriate including, without limitation, book-entry registration or issuance of a share certificate or certificates, creation of a new class of shares or amendment of the Memorandum and/or Articles of Association of the
Company. In the event any share certificate is issued in respect of Restricted Shares granted under this 2021 Global Share Plan, such certificate shall be registered in the name of the Participant and shall bear an appropriate legend referring to
the terms, conditions, and restrictions applicable to such Restricted Share. 
 Section 9. Other Share-Based Awards. 

The Committee is hereby authorized to grant to Participants such other Awards (including, without limitation, share appreciation rights and
rights to dividends and dividend equivalents) that are denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to, Shares (including, without limitation, securities convertible into Shares) as are
deemed by the Committee to be consistent with the purposes of this 2021 Global Share Plan. Subject to the terms of this 2021 Global Share Plan, the Committee shall determine the terms and conditions of such Awards. Shares or other securities
delivered pursuant to a purchase right granted under this Section 9 shall be purchased for such consideration, which may be paid by such method or methods and in such form or forms, including, without limitation, cash, Shares, other securities,
other Awards, or other property, or any combination thereof, as the Committee shall determine, the value of which consideration, as established by the Committee, shall, except in the case of Substitute Awards, not be less than the Fair Market Value
of such Shares or other securities as of the date such purchase right is granted. 
 Section 10. General Provisions Applicable to
Awards. 
 (a) All Awards shall be evidenced by an Award Agreement between the Company and each Participant. 

(b) Awards shall be granted for no cash consideration or for such minimal cash consideration as may be required by Applicable Laws. 

(c) Awards may, in the discretion of the Committee, be granted either alone or in addition to or in tandem with any other Award or any award
granted under any other plan of the Company. Awards granted in addition to or in tandem with other Awards, or in addition to or in tandem with awards granted under any other plan of the Company, may be granted either at the same time as or at a
different time from the grant of such other Awards or awards. 

  
 4 

 (d) Subject to the terms of this 2021 Global Share Plan, payments or transfers to be made by
the Company upon the grant, exercise or payment of an Award may be made in such form or forms as the Committee shall determine including, without limitation, cash, Shares, other securities, other Awards, or other property, or any combination
thereof, and may be made in a single payment or transfer, in installments, or on a deferred basis, in each case in accordance with rules and procedures established by the Committee. Such rules and procedures may include, without limitation,
provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of dividend equivalents in respect of installment or deferred payments. 

(e) Unless the Committee shall otherwise determine, no Award and no right under any such Award, shall be assignable, alienable, saleable or
transferable by a Participant otherwise than by will or by the laws of descent and distribution; provided, however, that, if so determined by the Committee, a Participant may, in the manner established by the Committee, designate a beneficiary or
beneficiaries to exercise the rights of the Participant, and to receive any property distributable, with respect to any Award upon the death of the Participant. Each Award, and each right under any Award, shall be exercisable during the
Participant’s lifetime only by the Participant or, if permissible under Applicable Laws, by the Participant’s guardian or legal representative. No Award and no right under any such Award, may be pledged, charged, mortgaged, alienated,
attached, or otherwise encumbered, and any purported pledge, charge, mortgage, alienation, attachment or encumbrance thereof shall be void and unenforceable against the Company. The provisions of this paragraph shall not apply to any Award which has
been fully exercised, earned or paid, as the case may be, and shall not preclude forfeiture of an Award in accordance with the terms thereof. 

(f) All certificates for Shares or other securities delivered under this 2021 Global Share Plan pursuant to any Award or the exercise thereof
shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under this 2021 Global Share Plan or the rules, regulations, and other requirements of the United States Securities and Exchange Commission, any
stock exchange upon which such Shares or other securities are then listed, and any Applicable Laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 

(g) No Shares shall be delivered under the 2021 Global Share Plan to any Participant until such Participant has made arrangements acceptable
to the Committee for the satisfaction of any income and employment tax withholding obligations under Applicable Laws. The Company or any of its subsidiaries shall have the authority and the right to deduct or withhold, or require a Participant to
remit to the Company or its subsidiaries, an amount sufficient to satisfy all applicable taxes (including the Participant’s payroll tax obligations) required or permitted by Applicable Laws to be withheld with respect to any taxable event
concerning a Participant arising as a result of the 2021 Global Share Plan. The Committee may in its discretion and in satisfaction of the foregoing requirement allow a Participant to elect to have the Company withhold Shares otherwise issuable
under an Award (or allow the return of Shares) having a Fair Market Value equal to the sum required to be withheld. Notwithstanding any other provision of the 2021 Global Share Plan, the number of Shares which may be withheld with respect to the
issuance, vesting, exercise or payment of any Award (or which may be repurchased from the Participant of such Award after such Shares were acquired by the Participant from the Company) in order to satisfy any income and payroll tax liabilities
applicable to the Participant with respect to the issuance, vesting, exercise or payment of the Award shall, unless specifically approved by the Committee, be limited to the number of Shares which have a Fair Market Value on the date of withholding
or repurchase equal to the aggregate amount of such liabilities based on the minimum statutory withholding rates for the applicable income and payroll tax purposes that are applicable to such supplemental taxable income. 

Section 11. Amendment and Termination. 

(a) Except to the extent prohibited by Applicable Laws and unless otherwise expressly provided in an Award Agreement or in this 2021 Global
Share Plan, the Committee may amend, alter, suspend, discontinue or terminate this 2021 Global Share Plan, or any Award Agreement hereunder or any portion hereof or thereof at any time; provided, however, that no such amendment,
alteration, suspension, discontinuation or termination shall be made without (i) shareholder approval, if such approval is necessary to comply with any tax or regulatory requirement for which or with which the Committee deems it necessary or
desirable to qualify or comply, (ii) shareholder approval as provided in the Company’s Memorandum and Articles of Association for any amendment to this 2021 Global Share Plan that increases the total number of Shares reserved for the
purposes of this 2021 Global Share Plan, and (iii) with respect to any Award Agreement, the consent of the affected Participant, if such action would materially and adversely affect the rights of such Participant under any outstanding Award.

  
 5 

 (b) The Committee may waive any conditions or rights under, amend any terms of, or amend,
alter, suspend, discontinue or terminate, any Award theretofore granted, prospectively or retroactively, without the consent of any relevant Participant or holder or beneficiary of an Award; provided, however, that no such action shall
materially and adversely affect the rights of any affected Participant or holder or beneficiary under any Award theretofore granted under this 2021 Global Share Plan; and provided further that, except as provided in
Section 6(e) hereof, no such action shall reduce the exercise price of any Option established at the time of grant thereof. 
 (c) The
Committee shall be authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the events described in Section 6(e) hereof
affecting the Company, or the financial statements of the Company, or of changes in Applicable Laws or accounting principles); whenever the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the
benefits or potential benefits intended to be made available under this 2021 Global Share Plan. 
 (d) Any provision of this 2021 Global
Share Plan or any Award Agreement to the contrary notwithstanding, with the affected Participant’s consent, the Committee may cause any Award granted hereunder to be canceled in consideration of a cash payment or alternative Award made to the
holder of such canceled Award equal in value to the Fair Market Value of such canceled Award as of the time of the cancellation. 
 (e) The
Committee may correct any defect, supply any omission, or reconcile any inconsistency in this 2021 Global Share Plan or any Award in the manner and to the extent it shall deem desirable to carry this 2021 Global Share Plan into effect. 

Section 12. Withholding Taxes.

The exercise of each Award granted under this 2021 Global Share Plan shall be subject to the condition that, if at any time, the Committee
shall determine that the satisfaction of withholding tax is necessary or desirable in respect of such exercise, such exercise shall not be effective unless such withholding has been effected to the satisfaction of the Committee. In such
circumstances, the Committee may require the exercising Participant to pay to the Company, in addition to and in the same manner as the Exercise Price for the Award Shares, such amount as the Company or any Affiliate is obliged to remit to the
relevant taxing authority in respect of the exercise of the Awards. Alternatively, the Committee may direct the Company or an Affiliate thereof to withhold the appropriate amount of tax from the applicable Participant’s salary in connection
with a requested exercise. Any such additional payment shall be due no later than the date as of which any amount with respect to the Award exercised first becomes includable in the gross income of the exercising Participant for tax purposes.

 Section 13. Miscellaneous. 

(a) No employee, independent contractor, Participant or other person shall have any claim to be granted any Award under this 2021 Global Share
Plan, and there is no obligation for uniformity of treatment of employees, independent contractors, Participants, or holders or beneficiaries of Awards under this 2021 Global Share Plan. The terms and conditions of Awards need not be the same with
respect to each recipient. 
 (b) Nothing contained in this 2021 Global Share Plan shall prevent the Company from adopting or continuing in
effect other or additional compensation arrangements, and such arrangements may be either generally applicable or applicable only in specific cases. 

(c) The grant of an Award shall not be construed as giving a Participant the right to be retained in the employ or service of the Company or
any Affiliate. Further, the Company or the applicable Affiliate may at any time dismiss a Participant from employment or terminate the services of an independent contractor, free from any liability, or any claim under this 2021 Global Share Plan,
unless otherwise expressly provided in this 2021 Global Share Plan or in any Award Agreement or in any other agreement binding the parties. 

  
 6 

 (d) If any provision of this 2021 Global Share Plan or any Award is or becomes or is deemed
to be invalid, illegal, or unenforceable in any jurisdiction, or as to any person or Award, or would disqualify this 2021 Global Share Plan or any Award under any Applicable Laws, such provision shall (to the fullest extent permitted by Applicable
Laws) be construed or deemed amended to conform to Applicable Laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the intent of this 2021 Global Share Plan or the Award, such
provision shall be stricken as to such jurisdiction, person or Award, and the remainder of this 2021 Global Share Plan and any such Award shall remain in full force and effect. 

(e) Awards payable under this 2021 Global Share Plan shall be payable in Shares or from the general assets of the Company, and no special or
separate reserve, fund or deposit shall be made to assure payment of such awards. No Participant, beneficiary or other person shall have any right, title or interest in any fund or in any specific asset (including Shares, except as expressly
otherwise provided) of the Company or one of its subsidiaries by reason of any award hereunder. 
 (f) Neither this 2021 Global Share Plan
nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and a Participant. To the extent that any person acquires a right to receive payments from the Company pursuant
to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company. 
 (g) No fractional Shares
shall be issued or delivered pursuant to this 2021 Global Share Plan or any Award, and the Committee shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares, or whether such
fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated. 
 (h) This 2021 Global Share Plan shall be
submitted to the competent foreign exchange regulatory authority and tax authority of the PRC for registration if Applicable Laws require, and shall be implemented in accordance with the applicable rules of these authorities with respect to
Participants who are PRC residents. 
 (i) In order to assure the viability of Awards granted to Participants employed in various
jurisdictions, the Committee may, in its sole discretion, provide for such special terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy, or custom applicable in the jurisdiction in which the
Participant resides or is employed. Moreover, the Committee may approve such supplements to, amendments, restatements or alternative versions of this 2021 Global Share Plan as it may consider necessary or appropriate for such purposes without
thereby affecting the terms of this 2021 Global Share Plan as in effect for any other purpose; provided, however, that no such supplements, restatements or alternative versions shall increase the share limitations contained in
Section 6 hereof. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be granted, that would violate any Applicable Laws. 

(j) The Company shall not be obligated to grant any Awards, permit the exercise of any Awards, issue any Award Shares upon the exercise of any
Awards, make any payments or take any other action pursuant to this 2021 Global Share Plan if, in the opinion of the Committee, such action would conflict or be inconsistent with any Applicable Law, the Company’s trading policies or would
result in any delay or other issues in connection with an IPO, and the Committee reserves the right to refuse to take such action for so long as such conflict or inconsistency or issue remains outstanding. 

(k) The Company shall maintain a register of Awards granted to the Participants and Award Shares issued to the Participants or an entity
designated by the Participants, including the dates of grant of such Awards and the exercise of such Awards and any other details as the Committee may deem appropriate. 

(l) The 2021 Global Share Plan and all Award Agreements shall be governed by and construed in accordance with the laws of the PRC. 

  
 7 

 Section 14. Effective Date of 2021 Global Share Plan. 

The 2021 Global Share Plan shall be effective as of the effective date designated by the Board and the Members of the Company. 

Section 15. Term of 2021 Global Share Plan. 

No Award shall be granted under this 2021 Global Share Plan after the tenth anniversary of the effective date as determined in Section 14
hereof. However, unless otherwise expressly provided in this 2021 Global Share Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Committee to amend, alter, adjust, suspend,
discontinue, or terminate any such Award, or to waive any conditions or rights under any such Award, and the authority of the Board to amend this 2021 Global Share Plan, shall extend beyond such date. 

  
 8EX-10.13

 Exhibit 10.13 

 
  
  

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

by and among 
 LINKDOC
TECHNOLOGY LIMITED, 
 LINKDOC TECHNOLOGY HK LIMITED (零氪科技香港有限公司), 

LING KE INFORMATION TECHNOLOGY (BEIJING) CO., LTD.
(零氪信息技术(北
 京)
有限公司), 
 LING KE INVESTMENT
(TIANJIN) CO., LTD. (零氪投资(天津)有限公司), 
 THE PRC ENTITIES NAMED HEREIN, 

THE INVESTOR NAMED HEREIN 

and 
 THE FOUNDERS AND THE
FOUNDER ENTITIES NAMED HEREIN 
 Signing Date: February 10, 2021 

 
  
  

 TABLE OF CONTENTS 

 

							
	1.	  	 GENERAL MATTERS
	  	 	2	 
	  
	  	 1.1   Definitions
	  	 	2	 
	  
	  	 1.2   Warrantor Obligations.
	  	 	2	 
	2.	  	 SUBSCRIPTION AND ISSUANCE OF PREFERENCE SHARES.
	  	 	2	 
	  
	  	 2.1   Sale and Issuance of Series D+ Preference Shares.
	  	 	2	 
	  
	  	 2.2   Closing; Delivery.
	  	 	2	 
	3.	  	 REPRESENTATIONS AND WARRANTIES OF THE WARRANTORS.
	  	 	3	 
	  
	  	 3.1   Organization, Good Standing, Corporate Power and Qualification.
	  	 	3	 
	  
	  	 3.2   Capitalization.
	  	 	4	 
	  
	  	 3.3   Subsidiaries (General).
	  	 	6	 
	  
	  	 3.4   The WFOEs and PRC Entities.
	  	 	7	 
	  
	  	 3.5   Authorization.
	  	 	9	 
	  
	  	 3.6   Valid Issuance of Subscribed Shares.
	  	 	9	 
	  
	  	 3.7   Governmental Consents and Filings.
	  	 	10	 
	  
	  	 3.8   Litigation.
	  	 	10	 
	  
	  	 3.9   Intellectual Property.
	  	 	10	 
	  
	  	 3.10  Confidential Information and Invention Assignment Agreements.
	  	 	11	 
	  
	  	 3.11  Compliance with Other Instruments.
	  	 	11	 
	  
	  	 3.12  Agreements; Actions.
	  	 	12	 
	  
	  	 3.13  Certain Transactions.
	  	 	12	 
	  
	  	 3.14  Rights of Registration and Voting Rights.
	  	 	13	 
	  
	  	 3.15  Absence of Liens.
	  	 	13	 
	  
	  	 3.16  Company Activity.
	  	 	14	 
	  
	  	 3.17  Financial Statements.
	  	 	14	 
	  
	  	 3.18  Changes.
	  	 	14	 
	  
	  	 3.19  Liabilities.
	  	 	15	 
	  
	  	 3.20  Employee Matters.
	  	 	16	 
	  
	  	 3.21  Tax Matters.
	  	 	18	 
	  
	  	 3.22  CFC.
	  	 	20	 
	  
	  	 3.23  Foreign Investment in Real Property Tax Act of 1980 (FIRPTA).
	  	 	20	 
	  
	  	 3.24  Anti-Corruption
	  	 	20	 
	  
	  	 3.25  Brokers or Finders
	  	 	21	 
	  
	  	 3.26  Permits.
	  	 	21	 
	  
	  	 3.27  Corporate Documents.
	  	 	21	 

							
	  
	  	 3.28  Environmental and Safety Laws.
	  	 	21	 
	  
	  	 3.29  Privacy and Personal Data Protection.
	  	 	21	 
	  
	  	 3.30  HIPAA Compliance
	  	 	22	 
	  
	  	 3.31  OFAC Compliance
	  	 	22	 
	  
	  	 3.32  Compliance with Money Laundering Laws.
	  	 	23	 
	  
	  	 3.33  No Disqualification Events.
	  	 	23	 
	  
	  	 3.34  Disclosure.
	  	 	24	 
	  
	  	 3.35  Founders and Founder Entities.
	  	 	24	 
	  
	  	 3.36  System Security.
	  	 	25	 
	  
	  	 3.37  Restructuring Documents
	  	 	26	 
	  
	  	 3.38  Insurance.
	  	 	26	 
	4.	  	 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.
	  	 	26	 
	  
	  	 4.1   Authorization.
	  	 	26	 
	  
	  	 4.2   Disclosure of Information.
	  	 	27	 
	5.	  	 CONDITIONS TO THE INVESTOR’S OBLIGATIONS AT CLOSING.
	  	 	27	 
	  
	  	 5.1   Representations and Warranties.
	  	 	27	 
	  
	  	 5.2   Performance.
	  	 	27	 
	  
	  	 5.3   Compliance Certificate.
	  	 	27	 
	  
	  	 5.4   Qualifications.
	  	 	27	 
	  
	  	 5.5   Laws
	  	 	27	 
	  
	  	 5.6   No Litigation; No Material Adverse Effect.
	  	 	27	 
	  
	  	 5.7   Opinions of Company Counsels.
	  	 	27	 
	  
	  	 5.8   Shareholders’ Agreement
	  	 	28	 
	  
	  	 5.9   Memorandum and Articles of Association.
	  	 	28	 
	  
	  	 5.10  Transaction Agreements
	  	 	28	 
	  
	  	 5.11  Chairman’s Certificate.
	  	 	28	 
	  
	  	 5.12  Proceedings and Documents.
	  	 	28	 
	  
	  	 5.13  Confidential Information and Invention Assignment Agreements
	  	 	28	 
	  
	  	 5.14  Due Diligence.
	  	 	28	 
	  
	  	 5.15  Business Cooperation
	  	 	28	 
	  
	  	 5.16  Amendment to Series D Purchase Agreement.
	  	 	28	 
	  
	  	 5.17  Amendment to Series D+ Purchase Agreement I
	  	 	29	 
	6.	  	 CONDITIONS TO THE COMPANY’S OBLIGATIONS AT CLOSING.
	  	 	29	 
	  
	  	 6.1   Representations and Warranties
	  	 	29	 
	  
	  	 6.2   Performance.
	  	 	29	 

  
 ii 

							
	  
	  	 6.3   Transaction Agreements.
	  	 	29	 
	7.	  	 COVENANTS.
	  	 	29	 
	  
	  	 7.1   Use of Proceeds
	  	 	29	 
	  
	  	 7.2   Availability of Shares
	  	 	30	 
	  
	  	 7.3   Business of the Company and the HK Entity.
	  	 	30	 
	  
	  	 7.4   Business Transfer.
	  	 	30	 
	  
	  	 7.5   Filing of the Memorandum and Articles of Association.
	  	 	30	 
	  
	  	 7.6   Compliance with Applicable Law.
	  	 	30	 
	  
	  	 7.7   Insurance Coverage.
	  	 	30	 
	  
	  	 7.8   Social Insurance, Housing Fund, Individual Income Tax, Value-Added Tax and
Local Levies, Corporate Income Tax and Other Applicable Taxes Compliance.
	  	 	31	 
	  
	  	 7.9   Publicity.
	  	 	31	 
	  
	  	 7.10  Investor Nominee.
	  	 	32	 
	  
	  	 7.11  Business Contracts of the Group Companies
	  	 	32	 
	  
	  	 7.12  Code of Data Classification Management and Conduct.
	  	 	34	 
	  
	  	 7.13  Personal Data Processing and Privacy Protection.
	  	 	34	 
	  
	  	 7.14  Compliance with Restructuring Documents.
	  	 	35	 
	  
	  	 7.15  Tax Compliance and Indemnity.
	  	 	35	 
	  
	  	 7.16  Capital Contribution of the WFOE I.
	  	 	35	 
	  
	  	 7.17  Further Assurances
	  	 	36	 
	  
	  	 7.18  Filing of Lease Agreements.
	  	 	36	 
	  
	  	 7.19  Patient Follow-up
	  	 	36	 
	  
	  	 7.20  Online Publishing Service License.
	  	 	36	 
	  
	  	 7.21  Anti-Corruption
	  	 	36	 
	  
	  	 7.22  Internal System.
	  	 	37	 
	  
	  	 7.23  Indemnification Agreement.
	  	 	37	 
	  
	  	 7.24  Budget.
	  	 	37	 
	  
	  	 7.25  Additional Covenants
	  	 	37	 
	  
	  	 7.26  Reclassification of Ordinary Shares.
	  	 	38	 
	8.	  	 CURE OF BREACHES; INDEMNITY.
	  	 	38	 
	9.	  	 GENERAL PROVISIONS.
	  	 	40	 
	  
	  	 9.1   Survival of Warranties.
	  	 	40	 
	  
	  	 9.2   FIRPTA Notice.
	  	 	40	 
	  
	  	 9.3   Successors and Assigns
	  	 	41	 
	  
	  	 9.4   Third Parties.
	  	 	41	 

  
 iii 

					
	  
	  	 9.5   Governing Law.
	  	41
	  
	  	 9.6   Counterparts; Facsimile
	  	41
	  
	  	 9.7   Interpretation; Titles and Subtitles.
	  	41
	  
	  	 9.8   Notices.
	  	41
	  
	  	 9.9   No Finder’s Fees.
	  	42
	  
	  	 9.10  Fees and Expenses.
	  	42
	  
	  	 9.11  Amendments and Waivers.
	  	42
	  
	  	 9.12  Severability
	  	42
	  
	  	 9.13  Delays or Omissions.
	  	42
	  
	  	 9.14  Entire Agreement.
	  	43
	  
	  	 9.15  Pronouns.
	  	43
	  
	  	 9.16  Dispute Resolution.
	  	43
	  
	  	 9.17  No Commitment for Additional Financing.
	  	44
	  
	  	 9.18  No Negotiation.
	  	44
	  
	  	 9.19  Exclusivity.
	  	44
	  
	  	 9.20  Termination.
	  	45

 LIST OF SCHEDULES AND EXHIBITS 
  

					
	 Schedule A
	 	–	    	Definitions
	 Schedule B
	 	–	    	Schedule of Investor
	 Schedule C
	 	–	    	Schedule of PRC Entities
	 Schedule D
	 	–	    	Schedule of Founders
	 Schedule E
	 	–	    	Capitalization Table of the Company
	 Schedule F
	 	–	    	Addresses for Notice
	 Exhibit A
	 	–	    	Disclosure Schedule
	 Exhibit B
	 	–	    	Key Employees
	 Exhibit C
	 	–	    	Shareholders’ Agreement
	 Exhibit D
	 	–	    	Sixth Amended and Restated Memorandum and Articles of Association
	 Exhibit E
	 	–	    	Form of Indemnification Agreement
	 Exhibit F
	 	–	    	Business Cooperation Agreement

  
 iv 

 SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

This Series D+ Preference Shares Subscription Agreement (this “Agreement”) is entered into as of February 10, 2021 among
the following parties: 
 A. LinkDoc Technology Limited, an exempted company incorporated with limited liability in the Cayman Islands (the
“Company”) with a registered address at the Office of Sertus Incorporations (Cayman) Limited, Sertus Chambers, P.O. Box 2547, Cassia Court, Camana Bay, Grand Cayman, Cayman Islands; 

B. LinkDoc Technology HK Limited
(零氪科技香港有限公司), a Hong Kong company with a registered
address at Room 1501 (682), 15/F., SPA Centre, 53-55 Lockhart Road, Wanchai, Hong Kong (the “HK Entity”); 
 C. Ling
Ke Information Technology (Beijing) Co., Ltd. (零氪信息技术(北京)有 限公司), a wholly-foreign owned enterprise established under the Laws of the PRC (the “WFOE I”) with a registered address at Zone ABCD, Floor 10, and Zone ACD, Floor 11, Block A, No.8
Haidian Street, Haidian District, Beijing, China; 
 D. Ling Ke Investment (Tianjin) Co., Ltd. (零氪投资(天津)有限公司), a wholly-foreign owned
enterprise established under the Laws of the PRC (the “WFOE II”, together with WFOE I, the “WFOEs” and each, a “WFOE”) with a registered address at 303, Building 4, No. 3, Hongkong Street,
Jinnan Economic Development Zone (Western District), Jinnan District, Tianjin, China; 
 E. The entities set forth on Schedule
C (collectively, the “PRC Entities” and each, a “PRC Entity”); 
 F. Alibaba Health (Hong Kong)
Technology Company Limited, a company established under the Laws of Hong Kong with a registered address at 26/F, Tower One Times Square, 1 Matheson Street, Causeway Bay, HK (the “Investor”); and 

G. The individuals set forth on Schedule D (collectively the “Founders” and each a “Founder”) and the
entities owned by such individuals as set forth opposite such individuals’ names on Schedule D (collectively the “Founder Entities” and each a “Founder Entity”). 

The Company, the WFOEs, the HK Entity, the PRC Entities, the Investor, the Founder Entities and the Founders are collectively referred to as
the “Parties”, and each, a “Party”. 
 RECITALS 

WHEREAS, the Investor has agreed to subscribe for and purchase from the Company, and the Company has agreed to issue and sell to the Investor
the Subscribed Shares (as defined below), upon the terms and conditions set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

	1.	 GENERAL MATTERS 

1.1 Definitions. Capitalized terms used herein without definition have the meanings assigned to them in Schedule A attached to
this Agreement. Unless otherwise set forth in Schedule A, the use of any term defined in Schedule A in its uncapitalized form indicates that the words have their normal and general meaning. 

1.2 Warrantor Obligations. Where this Agreement or any Transaction Agreement places an obligation on any Warrantor, each other
Warrantor shall use its best efforts to cause the obligated Warrantor to perform such obligation. 
  

	2.	 SUBSCRIPTION AND ISSUANCE OF PREFERENCE SHARES. 

2.1 Sale and Issuance of Series D+ Preference Shares. 

(a) The Company shall authorize, prior to the Closing (as defined below), (i) the sale and issuance of 21,669,131 Series D+ Preference
Shares (the “Subscribed Shares”), having the rights, privileges, preferences and restrictions set forth in the Sixth Amended and Restated Memorandum and Articles of Association of the Company approved and adopted by the Company in a
form as set forth in Exhibit D, effective subject to and contingent upon the Closing (the “Memorandum and Articles of Association”), (ii) the reservation of such number of the Company’s Ordinary Shares, US$0.00008
nominal or par value per share (the “Ordinary Shares”), for issuance upon conversion of the Subscribed Shares (the “Conversion Shares”), and (iii) the issuance of the Conversion Shares upon conversion of the
Subscribed Shares. 
 (b) Subject to the terms and conditions of this Agreement, at the Closing, the Company shall issue to the Investor,
and the Investor shall subscribe for the Subscribed Shares, at a subscription price of US$2.7372 per share for each Series D+ Preference Share, amounting to the aggregate amount set forth against the Investor’s name on Schedule B
attached hereto (the “Subscription Price”). 
 2.2 Closing; Delivery. 

(a) The subscription and issuance of the Subscribed Shares shall take place remotely via the exchange of documents and signatures at the
closing. The closing of subscription and issuance of the Subscribed Shares shall take place on the date no later than ten (10) Business Days after the fulfillment or waiver of the conditions to the Closing set forth in Section 5 hereof, or
at such other time and place as the Company and, the Investor mutually agree upon in writing (the “Closing”). 
 (b) At the
Closing, the Company shall deliver to the Investor (i) a scanned copy of the share certificate representing the Subscribed Shares being purchased by the Investor at the Closing, provided that the Company shall then deliver the original
share certificate to the Investor promptly (but in any event within five (5) Business Days) after the Closing, (ii) a copy of the Company’s updated register of members, certified by the secretary service provider of the Company as
true and complete as of the date of the Closing and reflecting the Investor as the holder of the Subscribed Shares at the Closing; and (iii) a copy of the Company’s register of directors, certified by the registered office provider of the
Company as true and complete as of the date of the Closing. 

  
 2 

 (c) At the Closing, the Investor shall deliver the aggregate Subscription Price, by wire
transfer in immediately available funds in U.S. dollar to a bank account of the Company. The details of such bank account of the Company shall be provided by the Company to the Investor in writing at least five (5) Business Days prior to the
Closing. 
  

	3.	 REPRESENTATIONS AND WARRANTIES OF THE WARRANTORS. 

Each Warrantor hereby severally and jointly represents and warrants to the Investor that, subject to the qualifications and exceptions as set
forth in the Disclosure Schedule attached hereto as Exhibit A, the contents and statements of which shall be deemed to be part of the representations and warranties made hereunder, the following representations are true and complete as of the
date hereof and as of the date of the Closing, except where a different date is otherwise indicated in such statements. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections contained in this
Section 3, and the disclosures in any section of the Disclosure Schedule shall qualify other sections in this Section 3 to the extent it is reasonably apparent from a reading of the disclosure that such disclosure is applicable to such
other sections and such disclosure include sufficient details to assess the nature and scope of the matters disclosed. 
 3.1
Organization, Good Standing, Corporate Power and Qualification. 
 (a) The Company is a company duly incorporated, validly existing
and in good standing under the Companies Act (as amended) of the Cayman Islands (the “Statute”) and has all corporate power and authority required (i) to own its properties and assets, and to carry on its business as presently
conducted and as presently proposed to be conducted, and (ii) to execute, deliver and perform its obligations under the Transaction Agreements. The Company is qualified to do business and is in good standing in each other jurisdiction where it
has an operation. 
 (b) The WFOE I is a company duly organized and validly existing under the Laws of the PRC, and has all necessary powers
and all necessary governmental licenses, permits, Governmental Authorizations, consents and approvals required (i) to own its properties and assets, and to carry on its business as presently conducted and as presently proposed to be conducted,
and (ii) to execute, deliver and perform its obligations under the Transaction Agreements. 
 (c) The WFOE II is a company duly
organized and validly existing under the Laws of the PRC, and has all necessary powers and all necessary governmental licenses, permits, Governmental Authorizations, consents and approvals required (i) to own its properties and assets, and to
carry on its business as presently conducted and as presently proposed to be conducted, and (ii) to execute, deliver and perform its obligations under the Transaction Agreements. 

(d) The HK Entity is a company duly organized, validly existing and in good standing under, and by virtue of, the Laws of Hong Kong, and has
all requisite power and authority (i) to own its properties and assets, and to carry on its business as presently conducted and as presently proposed to be conducted, and (ii) to execute, deliver and perform its obligations under the
Transaction Agreements. The HK Entity is qualified to do business and is in good standing in each jurisdiction where it has an operation. 

  
 3 

 (e) The Domestic Company is a limited liability company duly organized and validly existing
under the Laws of the PRC and, except as disclosed in Section 3.1(e) of the Disclosure Schedule, has all powers and all governmental licenses, permits, Governmental Authorizations, consents and approvals required (i) to own its properties
and assets, and to carry on its business as presently conducted and as presently proposed to be conducted, and (ii) to execute, deliver and perform its obligations under the Transaction Agreements. 

(f) Each of the PRC Entities (other than the Domestic Company) is a limited liability company or a limited partnership duly organized and
validly existing under the Laws of the PRC and has all powers and all governmental licenses, permits, Governmental Authorizations, consents and approvals required (i) to own its properties and assets, and to carry on its business as presently
conducted and as presently proposed to be conducted, and (ii) to execute, deliver and perform its obligations under the Transaction Agreements (if applicable). 

(g) No proceedings have commenced or are pending for the bankruptcy, insolvency, winding up, liquidation or reorganization of any Group
Company. No Group Company is bankrupt or insolvent. Each Group Company is able to pay its debts as they fall due and has sufficient assets to repay all of its debts. 

3.2 Capitalization. 
 (a)
The authorized share capital of the Company consists, immediately prior to the Closing (unless otherwise noted), of the following: 
 (x)
415,664,338 Ordinary Shares, (i) 100,625,000 shares of which are issued and outstanding immediately prior to the Closing, (ii) 43,570,953 of which are reserved for issuance to officers, directors, employees, consultants or service
providers of the Company pursuant to the Company’s Equity Plan, (iii) 22,058,825 shares of which are issuable upon conversion of the Series A Preference Shares, (iv) 46,218,488 shares of which are issuable upon conversion of the
Series B Preference Shares, (v) 2,899,160 shares of which are issuable upon conversion of the Series C-1 Preference Shares, (vi) 35,398,512 shares of which are issuable upon conversion of the Series C-2 Preference Shares,
(vii) 51,217,945 shares of which are issuable upon conversion of the Series D Preference Shares, (viii) 25,214,988 shares of which are issuable upon conversion of the Series D+ Preference Shares under the Series D+ Purchase Agreement I;
and (ix) 26,327,744 shares of which are issuable upon conversion of the Series D+ Preference Shares hereunder. All of the outstanding Ordinary Shares are duly authorized, validly issued, fully paid and nonassessable and were issued in material
compliance with all applicable U.S. federal, state or non-U.S. securities laws and regulations, including the Securities Act. 
 (y)
209,335,662 Preference Shares, (i) 22,058,825 of which are designated as Series A Preference Shares, all of which are issued and outstanding immediately prior to the Closing, (ii) 46,218,488 of which are designated as Series B Preference
Shares, all of which are issued and outstanding immediately prior to the Closing, (iii) 2,899,160 of which are designated as Series C-1 Preference Shares, all of which are issued and outstanding immediately prior to the Closing,
(iv) 35,398,512 of which are designated as Series C-2 Preference Shares, 30,924,371 of which are issued and outstanding immediately prior to the Closing, (v) 51,217,945 of which are designated as Series D Preference Shares, 49,346,520 of
which are issued and outstanding immediately prior to the Closing, and (vi) 51,542,732 of which are designated as Series D+ Preference Shares, 11,819,526 of which are issued and outstanding immediately prior to the Closing and 26,327,744 of
which are to be issued and outstanding immediately upon the Closing. None of the rights, preferences and powers of, or the restrictions on, the Preference Shares set forth in the Memorandum and Articles of Association are prohibited by the Statute.
Upon the Closing, each outstanding Preference Share will initially be convertible into one (1) Ordinary Share. 

  
 4 

 (b) There are no outstanding preemptive rights, options, warrants, conversion privileges or
rights (including but not limited to rights of first refusal or similar rights), orally or in writing, to purchase or acquire any securities from the Company, including, without limitation, any Ordinary Shares, or Preference Shares, or any
securities convertible into or exchangeable or exercisable for Ordinary Shares or Preference Shares, except for (A) the conversion privileges of the Subscribed Shares to be issued under this Agreement pursuant to the terms of the Memorandum and
Articles of Association, (B) the options under the Series D+ Purchase Agreement I and the Option Agreements (as defined in Series D+ Purchase Agreement I), (C) the warrants under the Amended and Restated Warrant to Purchase Preference
Shares issued by the Company dated as of June 8, 2018 and the Warrant to Purchase Preference Shares issued by the Company dated as of June 8, 2018 and (D) the rights provided in Section 4 of the Shareholders’ Agreement.
Except as set forth in the Transaction Agreements, no Person (A) has been granted any ratchet, formula adjustment, or any other type of, protection against dilution of their ownership interest in the Company, (B) has been granted rights to
require the Company to repurchase any of the Company’s securities, (C) has been granted rights to receive the same or better rights in connection with any ownership interest in the Company as any other Person may receive either pursuant to
this Agreement or at any time hereafter, or (D) have been granted rights of redemption by the Company. No ratchet, formula adjustment, or any other type of, protection against dilution of any ownership interest in the Company has been
triggered, nor will be triggered by the transactions provided for in this Agreement or any other Transaction Agreements. 
 (c) None of the
Company’s share purchase agreements or share option documents contains a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding upon
the occurrence of any event or combination of events. Except as may be set forth in the Memorandum and Articles of Association, the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital shares. 

(d) Schedule E attached hereto sets forth a true and complete capitalization table of the Company on a fully-diluted basis immediately
prior to the Closing and immediately after the Closing, which shows a complete list of all outstanding shareholders, option holders, warrant holders, convertible note holders and other security holders of the Company at such time and lists the type
and number of securities held by each such holder. 

  
 5 

 3.3 Subsidiaries (General). The Company does not currently own or Control, directly
or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity, except for one hundred percent (100%) of the equity interest in the HK Entity, which
(i) owns one hundred percent (100%) of the equity interest in the WFOE I, which has entered into a series of Restructuring Documents with the Domestic Company, and (ii) owns one hundred percent (100%) of the equity interest in
the WFOE II. The equity interests in and assets of the HK Entity and the WFOEs are free and clear of all Liens, and no Person other than the Company has any right to participate in, or receive any payment based on any amount relating to, the
revenue, income, value or net worth of the HK Entity or the WFOEs or any component or portion thereof, or any increase or decrease on any of the foregoing. Except as described in the preceding sentence of this Section 3.3, the Company is not a
participant in any joint venture, partnership or similar arrangement. The Company’s interest in the Domestic Company held through the WFOE I through the Restructuring Documents is free and clear of any Liens, and no other Person has any right
to participate in, or receive any payment based on any amount relating to, the revenue, income, value or net worth of the Domestic Company or any component or portion thereof, or any increase or decrease in any of the foregoing. As of the date of
this Agreement and the date of the Closing, the Domestic Company is 74.50%, 12.40%, 10.00% and 3.10% held by the Key Founder, LI Liping (李丽平), LUO Ligang (罗立刚), and TANG Peng (汤鹏), respectively, and such Persons have obtained the equity holdings in the Domestic Company in compliance with
applicable Laws. As of the date of this Agreement and the date of the Closing, the Domestic Company owns one hundred percent (100%) of the equity interest of each of the Tianjin Subsidiary I, the Tianjin Subsidiary II, the Guangzhou Subsidiary,
the Ningxia Subsidiary, Real World, Lingbo Subsidiary, Kuaima Subsidiary, Yike Subsidiary, Hebei Subsidiary and Wuxi Subsidiary, and has obtained the equity interest in each of the Tianjin Subsidiary I, the Tianjin Subsidiary II, the Guangzhou
Subsidiary, the Ningxia Subsidiary, Real World, Lingbo Subsidiary, Kuaima Subsidiary, Yike Subsidiary, Hebei Subsidiary and Wuxi Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, Houpu
Subsidiary is 70.00% held by the Domestic Company, and it has obtained the equity holdings in Houpu Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, the Tianjin Subsidiary III is 100% held
by the Tianjin Subsidiary I, and it has obtained the equity holdings in Tianjin Subsidiary III in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, Linke Subsidiary is 79.90% held by the Tianjin
Subsidiary I, and it has obtained the equity holdings in Linke Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, Lingce Subsidiary is held by the Domestic Company and the Tianjin Subsidiary
I, respectively, and such Persons have obtained the equity holdings in Lingce Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, Yingke Subsidiary is 99% held by the Domestic Company, and it
has obtained the equity holdings in Yingke Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, Zhonghui Subsidiary is 70% held by the Domestic Company, and it has obtained the equity holdings
in Zhonghui Subsidiary in compliance with applicable Laws. As of the date of this Agreement and the date of the Closing, the JV Entity is 95.9060% held by the WFOE II, and it has obtained the equity holdings in JV Entity in compliance with
applicable Laws. As of the date of this Agreement and the date of the Closing, the Xiamen Subsidiary is 100% held by the Tianjin Subsidiary I, and it has obtained the equity holdings in Xiamen Subsidiary in compliance with applicable Laws. As of the
date of this Agreement and the date of the Closing, the Zhonghe Subsidiary is 100% held by the Houpu Subsidiary, and it has obtained the equity holdings in Zhonghe Subsidiary in compliance with applicable Laws. The Company’s interest in each of
the PRC Entities held through the WFOEs is free and clear of any Liens through the Restructuring Documents, and no other Person has any right to participate in, or receive any payment based on any amount relating to, the revenue, income, value or
net worth of each of the PRC Entities or any component or portion thereof, or any increase or decrease in any of the foregoing. There is no agreement between the Founders, any Group Company and/or any other Person with respect to the ownership or
Control of any of the Group Companies except as contemplated by the Transaction Agreements. Unless otherwise specified in the Transaction Agreements, no Group Company owns or Controls, or has ever owned or Controlled, directly or indirectly, any
interest or share in any other Person or is or was a participant in any joint venture, partnership or similar arrangement. No Group Company is obligated to make any investment in or capital contribution in or on behalf of any other Person. Unless
otherwise disclosed in the Disclosure Schedule, none of the Founders owns or Controls, or has ever owned or Controlled, directly or indirectly, any interest or share in any other Person or is or was a participant in any joint venture, partnership or
similar arrangement. 

  
 6 

 3.4 The WFOEs and PRC Entities. 

(a) One hundred percent (100%) of the equity interest of each WFOE are duly vested in the HK Entity as the sole investor in and owner of
each WFOE in accordance with applicable PRC Laws. One hundred percent (100%) of the equity interest of the Domestic Company are pledged to the WFOE I through the Restructuring Documents and in accordance with applicable PRC Laws. One hundred
percent (100%) of the equity interest of each of the Tianjin Subsidiary I, Tianjin Subsidiary II, the Guangzhou Subsidiary, the Ningxia Subsidiary, Real World, Lingbo Subsidiary, Kuaima Subsidiary, Yike Subsidiary, Hebei Subsidiary and Wuxi
Subsidiary are duly vested in the Domestic Company as the sole shareholder in and owner of the Tianjin Subsidiary I, Tianjin Subsidiary II, the Guangzhou Subsidiary, the Ningxia Subsidiary, Real World, Lingbo Subsidiary, Kuaima Subsidiary, Yike
Subsidiary, Hebei Subsidiary and Wuxi Subsidiary in accordance with applicable PRC Laws. Seventy percent (70.00%) of the equity interest of Houpu Subsidiary are duly vested in the Domestic Company as the shareholder of Houpu Subsidiary in
accordance with applicable PRC Laws. Seventy-nine point nine percent (79.90%) of the equity interest of Linke Subsidiary are duly vested in the Tianjin Subsidiary I as the shareholder of Linke Subsidiary in accordance with applicable PRC Laws.
One hundred percent (100%) of the partnership interest of Lingce Subsidiary are duly vested in the Domestic Company and the Tianjin Subsidiary I as the general partner and limited partner in Lingce Subsidiary. One hundred percent (100%) of
the equity interest of Xiamen Subsidiary are duly vested in the Tianjin Subsidiary I as the shareholder of Xiamen Subsidiary in accordance with applicable PRC Laws. One hundred percent (100%) of the equity interest of Tianjin Subsidiary III are
duly vested in the Tianjin Subsidiary I as the shareholder of Tianjin Subsidiary III in accordance with applicable PRC Laws. Ninety-nine percent (99%) of the partnership interest of Yingke Subsidiary are duly vested in the Domestic Company as
the general partner in Yingke Subsidiary. Seventy percent (70%) of the equity interest of Zhonghui Subsidiary are duly vested in the Domestic Company as the shareholder of Zhonghui Subsidiary in accordance with applicable PRC Laws. 95.9060% of
the equity interest of the JV Entity are duly vested in the WFOE II as the shareholder of the JV Entity in accordance with applicable PRC Laws as of the date of this Agreement and immediately prior to the Closing. 

(b) As of the Closing, there will be no bonds, debentures, notes or other indebtedness of any WFOE or any PRC Entity having the right to vote
(or convertible into, or exchangeable for, securities having the right to vote) on any matters on which the holder of equity interests of any WFOE or any PRC Entity may vote. There will be no voting trusts, shareholder agreements, proxies or other
agreements or understandings in effect with respect to the voting or transfer of any of the equity interests to which any WFOE or any PRC Entity is a party or by which it is otherwise bound. 

(c) Neither any WFOE nor any PRC Entity maintains any offices or branches or subsidiaries, except for its principal executive office as
reflected on its business license. 
 (d) The incorporation documents relating to the WFOEs and the PRC Entities will be valid and will have
been duly approved or issued, as applicable, by the appropriate PRC authorities and are valid and in full force. 

  
 7 

 (e) All consents, approvals, Governmental Authorizations, permits or licenses required under
PRC Laws for the due and proper establishment and operation of the WFOEs and the PRC Entities as currently operated, or contemplated immediately prior to the Closing to be operated, have been duly obtained from the appropriate PRC authorities and
are in full force and effect. 
 (f) All necessary filings and registrations with the PRC authorities required in respect of the WFOEs and
the PRC Entities and their respective operations, including without limitation, the registrations with the Ministry of Commerce, the State Administration of Industry and Commerce, the State Administration for Foreign Exchange
(“SAFE”), tax bureau, or the local counterpart of each of the abovementioned governmental authorities, as applicable, have been duly completed in accordance with the relevant Laws. Except as disclosed in Section 3.4(f) of the
Disclosure Schedule, all required registrations, if any, pursuant to Circular 37, have been filed and accepted by SAFE. To the Knowledge of each Warrantor, there exists no grounds on which any of the Group Companies or the Investor may be subject to
Liability or penalties for failure or defect of registration, misrepresentation or failure to disclose material information to the issuing SAFE authority. All the application materials which have been or will be submitted to the government to obtain
or complete the above registrations, filings and approvals contain no material error, misstatement or fraudulent information. 
 (g) Neither
any WFOE nor any PRC Entity has received any letter or notice from any relevant Governmental Authority notifying any WFOE or any PRC Entity of the revocation of any Governmental Authorizations, permits or licenses issued to it for non-compliance or
the need for compliance or remedial actions in respect of the activities carried out directly or indirectly by any WFOE or any PRC Entity. 

(h) With respect to any land use right, building, property and investment held or leased by the WFOEs and the PRC Entities, they have
exclusive, full and unimpaired legal and beneficial ownership of their respective rights, leasehold interests, property and investments free from any mortgages or security interests of any nature, third party rights, conditions, orders or other
restrictions and has obtained all necessary approvals and effected all necessary registrations with Governmental Authorities with respect thereto. 

(i) Each of the WFOEs and the PRC Entities has been conducting its business activities within the permitted scope of business or is otherwise
operating its business in full compliance with all relevant legal requirements, requisite licenses, permits and approvals granted by competent PRC authorities. 

(j) No Warrantor has any reason, whether present or reasonably foreseeable, to believe that any Governmental Authorizations, licenses or
permits requisite for the conduct of any part of any WFOE’s or any PRC Entity’s business which are subject to periodic renewal will not be granted or renewed by the relevant PRC authorities. 

(k) All applicable Laws with respect to the opening and operation of foreign exchange accounts and foreign exchange activities of any WFOE or
any PRC Entity have been complied with in all material respects, and all requisite approvals from SAFE in relation thereto have been duly obtained. 

(l) With regard to employment and staff or labour management, each of the WFOEs and the PRC Entities has complied with all applicable PRC Laws
in all material respects, including Laws pertaining to employment contract, social insurance, medical insurance, housing funds or the like. 

  
 8 

 (m) There are no outstanding options with respect to any WFOE or any PRC Entity except as
contemplated under the Transaction Agreements. 
 (n) Other than the HK Entity, the PRC Entities and the WFOEs, there are no other
companies, partnerships, joint ventures, associations or other entities in which the Company owns, of record or beneficially, any direct or indirect equity or other interest or any right (contingent or otherwise) to acquire the same. 

(o) Each of the WFOEs and the PRC Entities owns free and clear from any Liens and third party rights all properties and assets, including all
such Proprietary Rights, necessary for its operations as presently conducted and as presently proposed to be conducted. 
 3.5
Authorization. All corporate action has been taken, or will be taken prior to the Closing, on the part of each Group Company and its officers, directors and members or shareholders that is necessary for (a) adoption of the Memorandum and
Articles of Association, (b) the authorization, execution and delivery of the Transaction Agreements by such Group Company, (c) the performance by such Group Company of the obligations to be performed by it as of the date hereof under the
Transaction Agreements, and (d) the issuance of the Conversion Shares. The Transaction Agreements, when executed and delivered by the Group Companies, shall constitute valid and legally binding obligations of each Group Company, enforceable
against such Group Company in accordance with their respective terms, except (A) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting
the enforcement of creditors’ rights generally, (B) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (C) to the extent the indemnification provisions contained
in the Shareholders’ Agreement may be limited by applicable U.S. federal, state or foreign securities laws. 
 3.6 Valid Issuance of
Subscribed Shares. The Subscribed Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be duly authorized, validly issued, fully paid and nonassessable and free of
restrictions on transfer other than restrictions on transfer under the Transaction Agreements and/or the Memorandum and Articles of Association, applicable U.S. federal, state or non-U.S. securities laws and Liens created by or imposed by an
Investor. Based in part on the accuracy of the representations of the Investor in Section 4 hereof and subject to the filings described in Section 3.7 hereof, the offer, sale and issuance of the Subscribed Shares to be issued pursuant to
and in conformity with the terms of this Agreement and the issuance of the Conversion Shares, if any, to be issued upon conversion thereof for no additional consideration and pursuant to the Memorandum and Articles of Association, will be issued in
compliance with all applicable U.S. federal, state or non-U.S. securities Laws, including the Securities Act. The Conversion Shares have been duly reserved for issuance, and upon issuance in accordance with the terms of the Memorandum and Articles
of Association, will be duly authorized, validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements and/or the Memorandum and Articles of Association,
applicable U.S. federal, state or non-U.S. securities laws and Liens created by or imposed by the Investor. 

  
 9 

 3.7 Governmental Consents and Filings. Based in part on the accuracy of the
representations made by the Investor in Section 4 hereof, all consents, approvals, orders, authorizations or registrations, qualifications, designations, declarations or filings with any Governmental Authority (“Governmental
Authorizations”) on the part of each Group Company’s valid execution, delivery and performance of the Transaction Agreements have been obtained and are currently effective, except for (i) any filings pursuant to Regulation D of
the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner, and (ii) any Governmental Authorizations required to be procured or made after the Closing as provided under the Transaction
Agreements, which will be made within the time frame provided in the Transaction Agreements or, in the absence of such provision, in a timely manner. 

3.8 Litigation. There is no Action pending, or to the Knowledge of each Warrantor, threatened in writing (i) against any Group
Company, Founders and/or Founder Entities or (ii) against any consultant, officer, director or Key Employee of any Group Company arising out of his or her consulting, employment or board relationship with such Group Company or that could
otherwise materially impact such Group Company. The foregoing includes, without limitation, Actions pending or threatened involving the prior employment or consultancy of any consultant, employee, officer, director or Key Employee of any Group
Company or the services provided by any of the foregoing Persons in connection with the business of such Group Company. No Group Company or, to the Knowledge of each Warrantor, any of such Group Company’s consultants, officers, directors or Key
Employees, is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government body (in the case of consultants, officers, directors or Key Employees, such as would affect such Group
Company). There is no Action by any Group Company, Founders and/or Founder Entities pending or that any Group Company, Founders and/or Founder Entities intends to initiate. 

3.9 Intellectual Property. Each Group Company owns or possesses sufficient legal rights to all Group Company Intellectual Property
without any violation or infringement of the rights of others. No product or service marketed or sold (or proposed to be marketed or sold) by any Group Company violates or will violate any license or infringes or will infringe any rights to
Intellectual Property of any other party, including but not limited to any privacy of any other party. Other than with respect to commercially available software products under standard end-user object code license agreements, there is no
outstanding option, license, agreement, claim, Lien or shared ownership interest of any kind relating to any Group Company Intellectual Property, nor is any Group Company bound by or a party to any options, licenses or agreements of any kind with
respect to the Intellectual Property of any other Person. No Group Company has received any written communications alleging that any Group Company has violated or, by conducting its business, would violate any of the Intellectual Property of any
other Person. Each Group Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its
employees for their use in connection with such Group Company’s business. It will not be necessary for any Group Company to use any inventions of any of employees or consultants of any Group Company (or Persons any Group Company currently
intends to hire) made prior to their employment by or consulting relationship with such Group Company. Each current and former employee and consultant has fully and validly assigned and transferred to the respective Group Company all Intellectual
Property he or she owns that are related to such Group Company’s business as now conducted and as presently proposed to be conducted. Section 3.9 of the Disclosure Schedule lists all Group Company Intellectual Property that is registered
with a Governmental Authority. No Group Company has embedded any open source, copyleft or community source code in any of its products generally available or in development, including but not limited to any libraries or code licensed under any
General Public License, Lesser General Public License or similar license arrangement, in a manner that would require (or purport to require) the distribution of the source code of such software or prohibit (or purport to prohibit) any Group Company
from charging for the distribution or use of such software or otherwise limit such software’s use for commercial purposes. No government funding, facilities of any university, college or other educational institution or public research center
or funding from third parties was used in the development of any Group Company Intellectual Property. 

  
 10 

 3.10 Confidential Information and Invention Assignment Agreements. Each current
employee, consultant and officer of each Group Company has executed an agreement with such Group Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Investor. No current
employee or consultant or officer of any Group Company has excluded works or inventions from his or her assignment of inventions pursuant to such agreement. To the Knowledge of each Warrantor, no such employees or consultants or officers is in
violation thereof. 
 3.11 Compliance with Other Instruments. Except as disclosed in Section 3.11 of the Disclosure Schedule, no
Group Company (a) is or has been in violation or default of any provisions of any constitutional document of such Group Company (which include, as applicable, articles or certificate of incorporation, memoranda and/or articles of association,
bylaws, joint venture contracts and the like); (b) is or has been in violation or default of any judgment, order, writ or decree of any court or Governmental Authority; (c) is or has been in violation or default under any agreement,
instrument, contract, lease, note, indenture, mortgage or purchase order to which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule; or (d) is in violation or default of any provision of the Statute
or any Law applicable to such Group Company (including without limitation such Laws relating to privacy, Personal Data protection, medical records and health profile protection, cybersecurity, telecommunication business, Intellectual Property,
anti-monopoly, Tax, employment, and social welfare and benefits) in any material aspect. Except as disclosed in Section 3.11 of the Disclosure Schedule, no Group Company has been in violation or default of any provision of the Statute or any
Law applicable to such Group Company (including without limitation such Laws relating to privacy, Personal Data protection, medical records and health profile protection, cybersecurity, telecommunication business, Intellectual Property,
anti-monopoly, Tax, employment, and social welfare and benefits), which violation or default would have a Material Adverse Effect. Except as disclosed in Section 3.11 of the Disclosure Schedule, the Company has not stored or processed any
electronic Personal Data, medical record, health profile and other sensitive information on the Internet. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction
Agreements will not result in any such violation or default, or constitute, with or without the passage of time and giving of notice, either (A) a default under any such judgment, order, writ, decree, agreement, instrument, contract, lease,
note, indenture, mortgage or purchase order or (B) an event which results in the creation of any Lien upon any assets of any Group Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to
any Group Company. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any acceleration of benefits or obligations, with or
without the passage of time and giving of notice, under any such judgment, order, writ, decree, agreement, instrument, contract, lease, note, indenture, mortgage or purchase order. 

  
 11 

 3.12 Agreements; Actions. 

(a) For the purpose of this Section 3.12(a), a “Material Agreement” shall mean any of the agreements, understandings,
instruments, contracts or proposed transactions to which any Group Company is a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments to, any Group Company in excess of RMB1,000,000, (ii) the
license of any Intellectual Property to or from any Group Company other than licenses with respect to commercially available software products under standard end-user object code license agreements or standard customer terms of service and privacy
policies for Internet sites, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell the products of any Group Company to any other Person, or that limit any Group Company’s exclusive right to develop,
manufacture, assemble, distribute, market or sell its products, (iv) entered into any agreement, understanding or proposed transaction with any of its officers, directors, consultants, Key Employees, members of the immediate families of the
foregoing, or any Affiliate of any of the foregoing, or any entity, the shareholder of which is the foregoing; (v) entering into any agreement with any hospital, any office or department of any hospital and/or any pharmaceutical factory or
company; (vi) entering into any agreement regarding the use of the medical records; or (vii) indemnification by any Group Company with respect to infringements of Proprietary Rights other than standard customer or channel agreements. No
Group Company is in material breach of or default under any Material Agreement and, there is no current claim or, to the Knowledge of each Warrantor, threat that any Group Company is or has been in material breach of or default under any Material
Agreement. Each Material Agreement is in full force and effect and is enforceable by the respective Group Company in accordance with its respective terms, except as may be limited by (A) applicable bankruptcy, insolvency, reorganization or
others laws of general application relating to or affecting the enforcement of creditors’ rights generally, or (B) the effect of rules of law governing the availability of equitable remedies. To the Knowledge of each Warrantor, no other
party to a Material Agreement is in material default thereunder or in actual or anticipated material breach thereof. 
 (b) Except as
disclosed in Section 3.12(b) of the Disclosure Schedule, no Group Company has (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital shares, (ii) incurred
any indebtedness for money borrowed or incurred any other Liabilities (other than indebtedness or Liabilities that have already been fully satisfied or incurred in the ordinary course of business), (iii) made any loans or advances to any
Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. For the purposes of
Section 3.12(a) hereof and this Section 3.12(b), all indebtedness, Liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including Persons any Group Company has reason to
believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum U.S. dollar or RMB amounts of such Sections. 

(c) No Group Company is a guarantor or indemnitor of any indebtedness of any other Person. 

3.13 Certain Transactions. 

  
 12 

 (a) Other than (i) standard employee benefits generally made available to all
employees, (ii) standard director and officer indemnification agreements approved by the respective boards of directors, and (iii) the purchase of Ordinary Shares and the issuance of options to purchase Ordinary Shares, in each instance,
approved in the written resolutions or meetings minutes of the Board, there is no agreement, understanding or proposed transaction between any Group Company and any of its officers, directors, consultants, Key Employees, members of the immediate
families of the foregoing, or any Affiliate of any of the foregoing, or any entity, the shareholder of which is the foregoing. 
 (b) No
Group Company is indebted, directly or indirectly, to any of its directors, officers or employees or to their respective spouses, parents, or children or to any Affiliate of any of the foregoing, or to any entity, the shareholder of which is the
foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available to all employees. None of the
directors, officers or employees, or any members of their immediate families, or any Affiliate of the foregoing, of any Group Company, or any entity, the shareholder of which is the foregoing are, directly or indirectly, indebted to any Group
Company or, to the Knowledge of each Warrantor, have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any customers, suppliers, service providers, joint venture partners,
licensees and competitors of any Group Company or (ii) direct or indirect ownership interest in any Person with which any Group Company is affiliated or with which any Group Company has a business relationship, or any Person that competes with
any Group Company, except that directors, officers or employees or members or shareholders of a Group Company may own (A) capital shares of the Company and/or options to purchase such shares and (B) shares in (but not exceeding two percent
(2%) of the outstanding capital shares of) publicly traded companies that may compete with any Group Company. 
 (c) None of the
Founders either on his/her own account or through any of his/her Affiliates, or in conjunction with or on behalf of any other Person, carry on or are engaged, concerned or interested directly or indirectly whether as shareholder, director, employee,
partner, agent or otherwise carry on any business in competition with the business of any Group Company. Such Founder is not subject to any contracts or any other obligations which prohibit, restrict or otherwise adversely affect such Founder’s
investment or involvement in any Group Company. 
 3.14 Rights of Registration and Voting Rights. Except as provided in the
Shareholders’ Agreement, the Company is not under any obligation to register under the Securities Act (or any applicable securities of any jurisdiction other than the United States) any of its securities (whether currently outstanding or to be
issued in the future). Except as contemplated in the Shareholders’ Agreement, no member of the Company (other than the holders of Preference Shares) has entered into any agreement with respect to the voting of capital shares of the Company.

 3.15 Absence of Liens. The property and assets each Group Company owns are owned free and clear of all Liens, except for statutory
Liens for the payment of current Taxes that are not yet delinquent and Liens that arise in the ordinary course of business and do not materially impair such Group Company’s ownership or use of such property or assets. With respect to the
property and assets it leases, each Group Company is in compliance with such leases and, to the Knowledge of each Warrantor, holds a valid leasehold interest free of any Liens other than those of the lessors of such property or assets. 

  
 13 

 3.16 Company Activity. Except as disclosed in Section 3.16 of the Disclosure
Schedule, the Company was formed solely to acquire and hold shares of the HK Entity and an indirect equity interest in the WFOEs, and since its formation has not engaged in any business and has not incurred any Liability as of the date hereof except
in the ordinary course of acquiring its shares in the HK Entity and its indirect equity interest in the WFOEs and will not incur any other Liabilities prior to the Closing except in the ordinary course of acquiring its indirect equity interest in
the WFOEs. 
 3.17 Financial Statements. The unaudited consolidated financial statements of the Group Companies for each fiscal year
ended December 31, 2018, December 31, 2019 and December 31, 2020, respectively (including balance sheets, statements of income and statements of cash flows, collectively, the “Financial Statements” and
December 31, 2020 the “Financial Statements Date”) are in accordance with the books and records of the applicable Group Company. The Financial Statements show a true and fair view of the assets, Liabilities (actual, contingent
or otherwise) and financial position and affairs and operating results of Group Companies as of the respective dates, and for the respective periods, indicated therein, subject in the case of the unaudited Financial Statements to normal year-end
audit adjustments. Specifically, but not by way of limitation, the respective balance sheets of the Financial Statements disclose all of the Group Companies’ respective debts, Liabilities and obligations of any nature, whether due or to become
due, as of their respective dates (including, without limitation, absolute liabilities, accrued liabilities, and contingent liabilities) to the extent such debts, Liabilities and obligations are required to be disclosed. The Group Companies have
good and marketable title to all assets set forth on the balance sheets of the respective Financial Statements, except for such assets as have been spent, sold or transferred in the ordinary course of business since their respective dates. None of
the Group Companies is a guarantor or indemnitor of any indebtedness of any other Person. Each Group Company will maintain a standard system of accounting established and administered in accordance with generally accepted accounting principles as
required in the jurisdiction where it is incorporated. 
 3.18 Changes. Except as disclosed in Section 3.18 of the Disclosure
Schedule or required to be undertaken under this Agreement prior to the Closing since the Financial Statements Date, none of the following events has occurred with respect to any Group Company: 

(a) any change in the assets, Liabilities, financial condition or operating results of a Group Company, except immaterial changes in the
ordinary course of business; 
 (b) any material change in the contingent obligations of the Group Company by way of guarantee, endorsement,
indemnity, warranty or otherwise; 
 (c) any change in such Group Company’s business operation or transactions resulting in the
aggregate working capital of the Group Companies falling below RMB60,000,000 (for the purpose of this Section 3.18, the working capital of the Group Companies is equal to total current assets minus total current liabilities); 

(d) any material damage, destruction or loss, whether or not covered by insurance; 

(e) any waiver or compromise by a Group Company of a valuable right or of a material debt owed to it; 

  
 14 

 (f) any satisfaction or discharge of any Lien or payment of any material obligation by a
Group Company; 
 (g) any entry into, or change or amendment to, a material contract, agreement, or arrangement which a Group Company or any
of its assets is bound by or subject to; 
 (h) any material change in any compensation arrangement or agreement with any employee, officer,
director or member or shareholder of a Group Company; 
 (i) any resignation or termination of employment of any officer with the title of
vice president or above or Key Employee of a Group Company; 
 (j) any mortgage, pledge, transfer of a security interest in, or Lien,
created by a Group Company, with respect to any of its material properties or assets, except Liens for Taxes not yet due or payable and Liens that arise in the ordinary course of business and do not materially impair its ownership or use of such
property or assets; 
 (k) any loans or guarantees made by a Group Company to or for the benefit of its employees, officers or directors, or
any members of their immediate families, other than travel advances and other advances made in the ordinary and customary course of its business; 

(l) any dividend, declaration, setting aside or payment or other distribution in respect of any of a Group Company’s capital shares, or
any direct or indirect redemption, purchase, or other acquisition of any of such shares by a Group Company; 
 (m) any sale, assignment,
transfer, or exclusive license of any material Group Company Intellectual Property or other material intangible assets of the Group Company; 

(n) receipt of notice that there has been a loss of, or material order cancellation by, any major customer of a Group Company; 

(o) any material failure to conduct business in the ordinary course, consistent with the Group Company’s past practices; 

(p) any transactions of any kind with any of its officers, directors or employees, or any members of their immediate families, or any entity
controlled by any of such individuals; 
 (q) any other event or condition of any character, other than any change of Law or policy, or any
events affecting the economy or a Group Company’s industry generally, that would reasonably be expected to result in a Material Adverse Effect; or 

(r) any arrangement or commitment by a Group Company to do any of the things described in this Section 3.18. 

3.19 Liabilities. Except as reflected in the Financial Statements, no Group Company has any indebtedness for borrowed money or other
Liabilities that it has directly or indirectly created, incurred, assumed, or guaranteed, or with respect to which the Group Company has otherwise become directly or indirectly liable, except (i) those incurred during ordinary course of
business, (ii) outstanding loans under the Convertible Loan Agreement dated September 1, 2017 and the Supplemental Convertible Loan Agreement dated June 8, 2018 by and among Ningbo Huiqiao Hongjia Equity Investment Limited Partnership
(宁波汇桥弘甲股权投资合伙企业(有限合伙)), the Company and the Domestic
Company, and the Convertible Loan Agreement dated June 8, 2018 by and among Ningbo Huiqiao Hongbo Equity Investment Limited Partnership
(宁波汇桥弘博股权投资合伙企业(
有限合伙)), the Company and the Domestic Company. 

  
 15 

 3.20 Employee Matters. 

(a) To the Knowledge of each Warrantor, none of the employees, consultants, or independent contractors of any Group Company is obligated under
any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such Person’s ability to
promote the interest of any Group Company or that would conflict with any Group Company’s business. Neither the execution or delivery or performance of the Transaction Agreements by any Group Company, nor the carrying on of any Group
Company’s business by its employees, consultants, or independent contractors, nor the conduct of any Group Company’s business as now conducted and as presently proposed to be conducted, will, to the Knowledge of each Warrantor, conflict
with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee, consultant, or independent contractor is now obligated. 

(b) To the Knowledge of each Warrantor, no Key Employee intends to terminate employment with any Group Company or is otherwise likely to
become unavailable to continue employment as a Key Employee, nor does any Group Company have a present intention to terminate the employment of any of the foregoing. Except as disclosed in Section 3.20(b) of the Disclosure Schedule, each officer and
Key Employee of each Group Company is currently devoting all of his or her business time to the conduct of such Group Company’s business. Except as disclosed in Section 3.20(b) of the Disclosure Schedule, no Group Company is aware that any
of its officers and Key Employees is planning to work less than full-time for such Group Company in the future. Except otherwise required by applicable Law, the employment of each employee of each Group Company is terminable at the will of such
Group Company. Except as required by applicable Law, upon termination of the employment of any such employees, no severance or other payments will become due. No Group Company has any policy, practice, plan, or program of paying severance pay or any
form of severance compensation in connection with the termination of employment or services. 
 (c) No Group Company has made any
representations regarding equity incentives or compensation to any officer, employees, director or consultant that are inconsistent with the share amounts and terms set forth in the minutes of meetings of its board of directors, the representations
set forth herein, or the Disclosure Schedule. 
 (d) Section 3.20(d) of the Disclosure Schedule sets forth each employee benefit plan
maintained, established or sponsored by any Group Company, or in which any Group Company participates or to which any Group Company contributes. Each Group Company has made all required contributions and has no Liability to any such employee benefit
plan, and has complied in all respects with all applicable Laws for any such employee benefit plan. 
 (e) No Group Company is bound by or
subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested nor, to the Knowledge of each Warrantor,
has sought to represent any of the employees, representatives or agents of any Group Company. There is no strike or other labor dispute involving any Group Company pending, or to the Knowledge of each Warrantor, threatened, nor is any Group Company
aware of any labor organization activity involving its employees. 

  
 16 

 (f) No Group Company is delinquent in payments to any of its employees, consultants, or
independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants, or independent contractors.
Each Group Company has complied in all material respects with all applicable Laws related to employment, including those related to wages, hours, worker classification, equal employment opportunity and collective bargaining. Except as disclosed in
Section 3.20(f) of the Disclosure Schedule, each Group Company has withheld and paid to the appropriate Governmental Authority or is holding for payment not yet due to such Governmental Authority all amounts required to be withheld from its
employees, consultants, or independent contractors and is not liable for any arrears of wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it, Taxes, penalties, or other sums for failure to comply with
any of the foregoing. Except as disclosed in Section 3.20(f) of the Disclosure Schedule, each Group Company, if applicable, is in compliance with any law relating to the provision of any form of social insurance to its employees, including,
without limitation, the social insurance and the housing fund payments, withholdings and contributions required under applicable PRC Law, and has paid, or made provision for the payment of, all such amounts as required under applicable Law. 

(g) Each former Key Employee (if any) whose employment was terminated by a Group Company has agreed in writing to fully release any claims
against such Group Company or any related party arising out of such employment. 
 (h) To the Knowledge of each Warrantor, none of the Key
Employees, officers or directors (except for the Preference Directors) of a Group Company has been (i) subject to voluntary or involuntary petition under any applicable bankruptcy Laws or insolvency Law or the appointment of a receiver, fiscal
agent or similar officer by a court for his business or property; (ii) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (iii) subject to any
order, judgment, or decree (not subsequently reversed, suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him from engaging, or otherwise imposing limits or conditions on his engagement in any
securities, investment advisory, banking, insurance, or other type of business or acting as an officer or director of a public company; or (iv) found by a court of competent jurisdiction in a civil action or by a government regulator to have
violated any applicable securities, commodities, or unfair trade practices Law, which such judgment or finding has not been subsequently reversed, suspended, or vacated. 

(i) As of the Closing, each Person who holds any currently outstanding Ordinary Shares or other securities of a Group Company or any option,
warrant or right to acquire such shares or other securities, has entered into or is otherwise bound by, an agreement granting such Group Company (i) the right to repurchase such shares for the original purchase price, or to cancel such option,
warrant or right, in the event the holder’s employment with or services for such Group Company is terminated or expires for any reason, subject to release of such repurchase or cancellation right on terms and conditions specified by the board
of directors of such Group Company, and (ii) a right of first refusal with respect to all such shares or other securities. 

  
 17 

 3.21 Tax Matters. 

(a) Each Group Company has duly and timely filed all Tax Returns and related tax information as required by all and applicable Law to have
been filed by it and all such Tax Returns are true, correct, and complete in all respects and were prepared in compliance with all applicable Laws. Each member of the Group Company has paid in full all Taxes (whether or not shown on any Tax Returns)
required to be paid by it. No Tax Liens (other than for current Taxes not yet due or payable) are currently in effect against any of the assets of any Group Company. Each Group Company has conducted its internal control and tax practice to comply
with all and applicable obligations as required by all and applicable Law, except for the change for the purpose of tax compliance. 
 (b)
The provisions for Taxes in the Financial Statements fully reflect all unpaid Taxes of each Group Company, whether or not assessed or disputed as of the date of the applicable Financial Statements. The unpaid Taxes of any Group Company (i) did
not, as of the date of the Financial Statements, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the Financial
Statements (rather than in any notes thereto) and (ii) do not exceed that reserve as adjusted for the passage of time through the Closing in accordance with the past custom and practice of each Group Company in filing their Tax Returns. 

(c) No tax audits or administrative or judicial Tax proceedings by any Governmental Authority with respect to the each Group Company is
currently in progress or, to the knowledge of the Company, has been threatened. No assessment of Tax has been proposed in writing against any Group Company or any of their assets or properties. No Group Company has received from any Governmental
Authority (including jurisdictions where a Group Company has not filed Tax Returns) any (i) notice indicating an intent to open audit or other review, (ii) request for information related to Tax matters, or (iii) notice of deficiency
or proposed adjustment for any amount of Tax proposed, asserted, or assessed by any Governmental Authority against any Group Company. No Group Company is subject to any waivers or extensions of applicable statutes of limitations with respect to
Taxes for any year. Except for extensions applied for and granted in the ordinary practice of the applicable jurisdiction, no Group Company currently is the beneficiary of any extension of time within which to file any Tax Return. 

(d) Since the Financial Statements Date, no Group Company has incurred any Taxes other than in the ordinary course of business consistent with
past custom and practice. No Group Company has received any claim from a Government Authority in a jurisdiction where a Group Company does not file Tax Returns that such Group Company is or may be subject to taxation by that jurisdiction. No Group
Company is treated as a resident for Tax purposes of, or is otherwise subject to income Tax in, or has branch, permanent establishment, agency of other taxable presence in, any jurisdiction other than the jurisdiction in which it has been
established. 
 (e) Each Group Company is in compliance in all respects with all terms, conditions and formalities necessary for the
continuance of any Tax exemption, Tax holiday, Tax credit, Tax incentive, Tax refund or other Tax reduction agreement or order available under any applicable Law. Each such Tax exemption, Tax holiday, Tax credit, Tax incentive, Tax refund or other
Tax reduction agreement or order (i) is expected to remain in full effect throughout the current effective period thereof after the Closing and is not subject to reduction, revocation, cancellation or any other changes (including retroactive
changes) in the future, and no Group Company has received any notice to the contrary or is aware of any event that may result in repeal, cancellation, revocation, or return of such entitlements. All exemptions, reductions and rebates of material
Taxes granted to any Group Company by a Governmental Authority are in full force and effect and have not been terminated as evidenced with valid governmental approvals. No Group Company is responsible for Taxes of any other Person by reason of
contract, successor liability, operation of Law or otherwise. No Group Company is, or has been, party to, involved with, bound by or otherwise subject to any Tax-sharing agreement, Tax-allocation agreement or similar agreement. 

  
 18 

 (f) No Group Company will be required to include material amounts in income, or exclude
material items of deduction, or qualification for Tax exemption, Tax holiday, Tax credit, Tax incentive or Tax refund, in any taxable period beginning after the Closing as a result of (i) a change in method of accounting occurring on or prior
to the Closing, except for the change for the purpose of tax compliance (ii) agreement with any Governmental Authority executed on or prior to the Closing, (iii) installment sale or open transaction disposition made on or prior to the
Closing, or (iv) prepaid amount received on or prior to the Closing. The transactions contemplated under this Agreement and the other Transaction Agreements to which any member of the Group Company is a party are not in violation of any
applicable Law regarding Tax, and will not result in any Tax exemption, Tax holiday, Tax credit, Tax incentive, Tax refund being revoked, cancelled or terminated or trigger any Tax liability for the Group Company. 

(g) No Group Company (i) has been a member of an affiliated group filing a consolidated Tax Return (other than an affiliated group the
common parent of which is the Company) or (ii) has any Liability for the Taxes of any Person (other than the Group Company) as a result of the Group Company being part of or owned by, or ceasing to be party of or owned by, an affiliated,
combined, consolidated, unitary or other similar group prior to the Closing, as a transferee or successor, by contract or otherwise. 
 (h)
Each Group Company has not entered into: (a) any transaction the sole or main purpose of which was the avoidance or deferral or reduction of tax by each Group Company or any associated person; or (b) or any transaction the object of which
was the exclusion or reduction of the amount of any income, profits, gains, sales, supplies or imports made or enjoyed by each Group Company or any associated person for any tax purpose, or the creation or increase of the amount of any deduction,
loss, allowance or credit claimed or intended to be claimed by each Group Company or any associated person for any Tax purpose, that may be challenged, disallowed or investigated by any Governmental Authority. 

(i) Each Group Company has complied with all statutory provisions rules, regulations, orders and directions in respect of any value added or
similar Tax on consumption, has promptly submitted accurate returns, maintains full and accurate records, and has never been subject to any interest, forfeiture, surcharge or penalty and is not a member of a group or consolidation with any other
company for the purposes of value added Tax. 
 (j) The Disclosure Schedule contains details of any legally binding arrangement with any
Governmental Authority with respect to any tax exemption, refund or reduction arrangement relating to any Group Company. 
 (k) No Group
Company has filed any U.S. Tax election, including any entity classification election pursuant to any applicable U.S. Treasury Regulations (the “Regulations”). The Company is not a “passive foreign investment company”
within the meaning of Code Section 1297(a). Except as set forth in the Disclosure Schedule, no Group Company owns a less than 25% equity interest (by value) in any other entity. 

  
 19 

 (l) The Company will not be required to pay any Taxes under PRC law (including, without
limitation, pursuant to PRC Announcement 7) with respect to the transactions contemplated by this Agreement. 
 3.22 CFC. Giving
effect to the transactions contemplated by this Agreement and the other Transaction Agreements, none of the Group Companies is, or expects to become, a “Controlled Foreign Corporation (CFC)” within the meaning of Section 957 of the
Code. For United States tax classification purposes the Company is classified as an association taxable as a corporation pursuant to Section 301.7701-2 of the Regulations. No election has been made under Section 301.7701-3 of the
Regulations to treat the Company or any Group Company as a partnership or disregarded entity for United States Tax purposes. 
 3.23
Foreign Investment in Real Property Tax Act of 1980 (FIRPTA). The Company is not now and has never been a “United States real property holding corporation” within the meaning of Section 897(c)(2) of the Code and
Section 1.897 2(b) of the Regulations. The Company has filed with the United States Internal Revenue Service all statements, if any, with its United States income Tax returns, which are required under Section 1.897 2(h) of the Regulations.

 3.24 Anti-Corruption. None of (i) any Group Company, any Founder or any Founder Entity (ii) any director, officer,
employee, Affiliate of any Group Company or any Founder Entity, or (iii) any Person acting on behalf of the foregoing (each of (i), (ii) and (iii) and collectively, a “Company Representative”), is aware of, has taken
or will take any action, directly or indirectly, with respect to itself or its operations or any of its investments, or any transaction contemplated by this Agreement and the other Transaction Agreements, in furtherance of any offer, gift, payment,
promise to pay or authorization or approval of any Prohibited Payment. For purposes of this Section 3.24, “Prohibited Payment” shall mean any offer, gift, payment, promise to pay or authorization of the payment of any money or
anything of value, (A) directly or indirectly, to or for the use or benefit of any Governmental Official (including to any person while knowing or having reason to know that all or a portion of the payment will be offered, given, or promised to
an Governmental Official) for the purpose of influencing any act or decision or omission of any Governmental Official or in order to obtain, retain or direct business to, to secure any improper benefit or advantage, or to induce an Governmental
Official to influence or affect any act or decision of any Governmental Authority, (B) that such Company Representative knew or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or
promised, directly or indirectly, for the aforementioned purposes, or (C) which is otherwise in violation of or having violated the U.S. Foreign Corrupt Practices Act, the United Kingdom Bribery Act, the People’s Republic of China Criminal
Law, the People’s Republic of China Anti-Unfair Competition Law, or any other applicable anti-bribery or anti-corruption Laws, in each cases as amended from time to time. None of the Company Representatives has accepted any Prohibited Payment.
None of the Group Companies or, to the Knowledge of the Warrantors, any of their respective administrators, officers or the Founders has made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or
retained any funds in violation of any applicable Laws subject to applicable exceptions and affirmative defenses. 

  
 20 

 3.25 Brokers or Finders. Except as disclosed in Section 3.25 of the Disclosure
Schedule, no Group Company has incurred, and will not incur, directly or indirectly, as a result of any action taken by such Group Company, any Liability for brokerage or finders’ fees or agents’ commissions or any similar charges in
connection with this Agreement or any other Transaction Agreement or any of the transactions contemplated hereby or thereby. 
 3.26
Permits. Except as disclosed in Section 3.26 of the Disclosure Schedule, each Group Company has all material permits, consents, licenses, approval, authorization and any similar authority granted by any Governmental Authority and any
other Person necessary for the conduct of its business. No Group Company is in default in any material respect under any of such permits, licenses or other similar authority. 

3.27 Corporate Documents. The Memorandum and Articles of Association shall be the effective memorandum and articles of association of
the Company immediately upon the Closing. The copy of the minute books of each Group Company provided to the Investor and its counsel contains minutes of all meetings of directors and members or shareholders and all actions by written consent
without a meeting by the directors and members or shareholders since the date of inception and accurately reflects in all material respects all actions by the directors (and any committee of directors) and members or shareholders of such Group
Company with respect to all transactions referred to in such minutes. 
 3.28 Environmental and Safety Laws. (a) Each Group
Company is and has been in compliance with all Environmental Laws; and (b) there has been no release, or to the Knowledge of each Warrantor, threatened release, of any pollutant, contaminant or toxic or hazardous material, substance or waste,
or petroleum or any fraction thereof (each a “Hazardous Substance”) on, upon, into or from any site currently or heretofore owned, leased or otherwise used by any Group Company. There are no material environmental records, reports,
notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies, and environmental studies or assessments arising out of or in connection with any Group Company’s business as presently conducted
and as presently proposed to be conducted. 
 3.29 Privacy and Personal Data Protection. 

(a) Except as disclosed in Section 3.29(a) of the Disclosure Schedule, the Group Companies have (i) duly provided data subjects
(including patients and hospitals) with relevant information and notices, which fully and accurately disclose how such Group Company Processes Personal Data and other sensitive data, and (ii) have obtained all rights, licenses, permissions,
registrations, notifications and consents from data subjects (including patients and hospitals), in each case required by all applicable Laws to Process Personal Data and other sensitive data to continue the business of any Group Company as
presently conducted. Except as disclosed in Section 3.29(a) of the Disclosure Schedule, the Group Companies have maintained in full force and effect such rights, licenses, permissions, registrations, notifications and consents. Except as
disclosed in Section 3.29(a) of the Disclosure Schedule, any Processing of Personal Data and other sensitive data by or on behalf of any and all of the Group Companies has been and is in accordance with such rights, licenses, permissions,
registrations, notifications and consents. Except when required by applicable Laws or as disclosed in Section 3.29(a) of the Disclosure Schedule, none of the Group Companies is restricted in Processing Personal Data in its possession or under its
control. The transactions contemplated by this Agreement or any other Transaction Agreement will not, as of the date of Closing, violate any privacy policies, terms of use, applicable Laws or contractual obligations relating to Processing of any
Personal Data or other sensitive data. 

  
 21 

 (b) The Group Companies (i) are and have been providing and securing sufficient and
adequate protection of Personal Data, confidential information, sensitive data, the privacy of the patients, physicians of hospitals, hospitals, including but not limited to the health profile and medical records thereof, from any unlawful or
unpermitted use, release, disclosure, display, modification, dissemination, transmission, hacking or other misuse, (ii) are and have been storing, keeping and maintaining the data, including Personal Data and other sensitive data they have
collected within the realm of the PRC; (iii) have not retained any Personal Data and other sensitive data for longer than necessary for the Processing of the Personal Data and other sensitive data; (iv) have not exported any data,
including Personal Data and other sensitive data, outside of the PRC in violation of any applicable Laws, including any applicable cybersecurity and data protection Law, (v) have never leaked any privacy of the patients, Personal Data and other
sensitive data Processed by the Group Companies, and (vi) are and have been complying at all times with applicable Laws in all material aspects. 

(c) Each Group Company has complied with all applicable Laws in all material aspects relating to transfer of the Personal Data and other
sensitive data to or from third parties (including cross-border transfer). Except as disclosed in Section 3.29 of the Disclosure Schedule, any use of the Personal Data or other sensitive data by the Group Companies and their Service Providers
(as defined in the Shareholders’ Agreement) are and have been in compliance with all applicable Laws and the contracts, to which any of such Group Companies is a party, in all material aspects. 

3.30 HIPAA Compliance. Subject to PRC Decree 1, the Group Companies are and have been operating their business in a way in compliance
with HIPAA in all material aspects. 
 3.31 OFAC Compliance. Neither the Company nor any Group Company, nor any directors, executive
officers, or members, nor to the knowledge of the Warrantors, any employees of the Company or any Group Company (i) is an OFAC Sanctioned Person (as defined below) or (ii) has violated, within the last five years, any OFAC Sanctions (as
defined below). Neither the Company nor any Group Company is located, organized or resident in or conducts or, within the past five (5) years, has conducted, business in, with, or involving any place that is subject to comprehensive OFAC
Sanctions, currently: Cuba, Iran, Sudan, Syria and the Crimea Region of Ukraine. Within the past five years, neither the Company nor any Group Company has made any voluntary disclosures to U.S. Government authorities under U.S. economic sanctions
laws or U.S. export control laws and, to the knowledge of the Warrantors, neither the Company nor any Group Company has been the subject of any governmental investigation or inquiry regarding the compliance of any of the Company or Group Companies
with such laws or been assessed any fine or penalty under such laws. Subject to PRC Decree 1, none of (i) the subscription and issuance of the Subscribed Shares, or issuance of the Conversion Shares, (ii) the execution, delivery and
performance of the Transaction Agreements, or (iii) the consummation of any transaction contemplated hereby or thereby, or the fulfillment of the terms hereof or thereof, result in a violation of any of the OFAC Sanctions (as defined below) or
of the Anti-Money Laundering Laws. The Group Company will not directly or indirectly use the proceeds of the offering of the securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner
or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or the target of OFAC Sanctions, (ii) to fund or facilitate any activities
of or business with any OFAC Sanctioned Person, or (iii) in any other manner that will result in a violation by any person of OFAC Sanctions (including any person participating in the transaction, whether as an investor or otherwise). 

  
 22 

 For the purposes of this Section 3.31: 

(a) “OFAC Sanctions” means any sanctions program administered by the Office of Foreign Assets Control of the United States
Department of the Treasury (“OFAC”) under authority delegated to the Secretary of the Treasury (the “Secretary”) by the President of the United States or provided to the Secretary by statute, and any order or
license issued by, or under authority delegated by, the President or provided to the Secretary by statute in connection with a sanctions program thus administered by OFAC. For ease of reference, and not by way of limitation, OFAC Sanctions programs
are described on OFAC’s website at www.treas.gov/ofac. 
 (b) “OFAC Sanctioned Person” means any government, country,
corporation or other entity, group or individual with whom or which the OFAC Sanctions prohibit a United States Person from engaging in transactions, and includes without limitation any individual or corporation or other entity that appears on the
current OFAC list of Specially Designated Nationals and Blocked Persons (the “SDN List”). For ease of reference, and not by way of limitation, OFAC Sanctioned Persons other than government and countries can be found on the SDN List
on OFAC’s website at www.treas.gov/offices/enforcement/ofac/sdn. 
 (c) “United States Person” means any United States
citizen, permanent resident alien, entity organized under the Laws of the United States (including foreign branches), or any Person (individual or entity) in the United States, and, with respect to the Cuban Assets Control Regulations, also includes
any corporation or other entity that is owned or controlled by one of the foregoing, without regard to where it is organized or doing business. 

3.32 Compliance with Money Laundering Laws. Subject to PRC Decree 1, the operations of the Group Companies are and have been conducted
at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions
where the Company or any of its subsidiaries conducts business, including the U.S. PATRIOT ACT of 2001, Her Majesty’s Treasury (HMT), the Organized and Serious Crimes Ordinance and the Anti-Money Laundering and Counter- Terrorist Financing
Ordinance of Hong Kong, and PRC anti-money laundering laws, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the
“Anti- Money Laundering Laws”), and no action suit or proceeding by or before any Governmental Authority or any arbitrator involving the Group Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the knowledge of the Warrantors, threatened. Subject to PRC Decree 1, the directors, officers, administrators, board of directors (supervisory and management), members and employees of the Group Companies are in compliance with, and
have not previously violated, the Anti-Money Laundering Laws. 
 3.33 No Disqualification Events. None of the Company, any of its
predecessors, any affiliated issuer, any director, executive officer or other officer of the Company participating in the offering, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the
basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”) is subject to any of the
“Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) of Regulation D promulgated under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3) of Regulation D promulgated under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. 

  
 23 

 3.34 Disclosure. 

(a) Each Warrantor has made available to the Investor all the information reasonably available to the Warrantors that the Investor has
requested for deciding whether to acquire the Shares (including all due diligence requests of the Investor and/or its counsel(s)). Such information includes certain of the Group Companies’ projections describing their proposed business plans.
Such business plans were prepared in good faith; however, the Warrantors do not warrant that they will achieve any results projected therein. 

(b) No representation or warranty of a Warrantor contained in this Agreement (as qualified by the Disclosure Schedule) and the Disclosure
Schedule, and no certificate furnished or to be furnished to Investor at the Closing contains any untrue statement of a material fact, or omits to state a material fact necessary in order to make the statements contained herein or therein not
misleading in light of the circumstances under which they were made. It is understood that this representation is qualified by the fact that no Warrantor has delivered to the Investor, nor has any Warrantor been requested to deliver, a private
placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities. 

(c) Each Warrantor has made available to the Investor all relevant information as requested by the Investor with respect to the agreements
entered into by the Company and the relevant hospitals and/or offices or departments of hospitals. 
 3.35 Founders and Founder
Entities. 
 (a) Each Founder Entity is a company duly organized, validly existing and in good standing under the Laws of its
jurisdiction of incorporation and has all corporate power and corporate authority required to execute, deliver and perform its obligations under the Transaction Agreements. 

(b) All corporate action has been taken, on the part of each Founder Entity and its officers, directors and members or shareholders that is
necessary for (i) the authorization, execution and delivery of the Transaction Agreements by such Founder Entity, and (ii) the performance by such Founder Entity of the obligations to be performed by it under the Transaction Agreements.
The Transaction Agreements, when executed and delivered by the Group Companies, shall constitute valid and legally binding obligations of each Founder Entity, enforceable against such Founder Entity in accordance with their respective terms, except
(A) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other Laws of general application relating to or affecting the enforcement of creditors’ rights generally, (B) as limited by
laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (C) to the extent the indemnification provisions contained in the Shareholders’ Agreement may be limited by applicable U.S.
federal, state or foreign securities laws. 

  
 24 

 (c) There are no outstanding loans, amounts payable or any other Liabilities between any
Group Company and any Founder or Founder Entity. None of the Founders and their respective Affiliates has, may have or may claim to have any claims, obligations or Liabilities against any Group Company. 

3.36 System Security. 

(a) Each of the Group Companies lawfully owns, leases or obtains a license to use all Systems that are currently deployed in the operation of
its business and will immediately retain such rights for the use of Systems that will be deployed after the Closing. None of the Group Companies is in breach of any of contracts or applicable Laws relating to the Systems. The Systems are reasonably
sufficient for the existing and expected needs of the Group Companies, are in satisfactory working order, and have been properly maintained by technically competent personnel, and in the last twelve (12) months immediately prior to the Closing,
there has not been, in relation to the Systems (or any elements thereof), any: (i) failures, breakdowns, performance disruptions, or interruptions of any of the Systems; or (ii) Security Breaches, which have had a Material Adverse Effect
on any of the Group Companies or caused material disruption, interruption or loss to the Group Companies. 
 (b) All of the Group Companies
have applied all security patches available for the Systems on a timely basis. The Group Companies have (i) implemented and maintained an information security program that (A) is comprised of reasonable organizational, physical,
administrative, and technical safeguards designed to (x) protect the security, confidentiality, integrity and availability of the Systems, including all Personal Data and other sensitive data Processed thereby, and (y) prevent the Systems
(and data therein) from being affected by a Security Breach, (B) is subject to the responsibility and oversight of the directors and executive officers of the Group Companies, and (C) is in accordance with applicable Laws and best industry
practices in each relevant jurisdiction, and (ii) has taken all commercially reasonable steps to implement such information security program, including through regular training, auditing, review, and remediation in accordance with best industry
information security practices and through the use of competent internal or external data security personnel or consultants. Each Group Company has taken commercially reasonable steps to provide for the backup and recovery of data and information
and, as applicable, has taken commercially reasonable steps to implement such plans and procedures. Each Group Company has implemented reasonable procedures to protect the Systems from all “back doors,” “Trojan horses,”
“worms,” “drop dead services,” “viruses” and other software that permit unauthorized use of, access to or disablement of any software, data or Systems. The Group Companies have not experienced any material unpermitted
intrusions or been adversely affected by and denial-of-service attacks. 
 (c) There have been no material incidents of (i) Security
Breaches or (ii) unauthorized access or unauthorized use of any Group Company’s Systems necessary for the operations of any Group Company’s business, and no Group Company has been required by any Governmental Authority to notify any
third party of any Security Breach. No Group Company has received a written notice (including any enforcement notice), letter or complaint from a Governmental Authority or any other third party alleging breach by it of any applicable Laws. No third
party has been awarded compensation by a Governmental Authority or by a court of law from any Group Company under any applicable Laws. No request has been made by a third party to, or order has been made by a Governmental Authority or a court of law
against, any Group Company for access to, the rectification, blocking, erasure or destruction of any Personal Data under any applicable Laws. 

  
 25 

 3.37 Restructuring Documents. 

(a) Each Restructuring Document constitutes a valid and legally binding obligation of the parties named therein enforceable in accordance with
its terms. 
 (b) The execution and delivery by each party named in each Restructuring Document, and the performance by such party of its
obligations thereunder and the consummation by it of the transactions contemplated therein shall not (i) result in any violation of, be in conflict with, or constitute a default under, with or without the passage of time or the giving of
notice, any provision of its corporate documents as in effect at the date hereof, or any contract to which a Group Company is a party or by which a Group Company is bound, (ii) accelerate, or constitute an event entitling any person to
accelerate, the maturity of any indebtedness or other Liability of any Group Company or to increase the rate of interest presently in effect with respect to any indebtedness of any Group Company, or (iii) result in the creation of any Lien upon
any of the properties or assets of any Group Company. 
 (c) All consents required in connection with the Restructuring Documents have been
made or unconditionally obtained in writing, and no such consent has been withdrawn or is subject to any condition precedent, which has not been fulfilled or performed. 

(d) Each Restructuring Document is in full force and effect and no party to any Restructuring Document is in breach or default in the
performance or observance of any of the terms or provisions of such Restructuring Document. None of the parties to any Restructuring Document has sent or received any communication regarding termination of or intention not to renew any Restructuring
Document, and no such termination or non-renewal has been threatened by any of the parties thereto. 
 (e) None of the Warrantors has
received any oral or written inquiries, notifications or any other form of official correspondence from any Governmental Authority challenging or questioning the legality or enforceability of the Restructuring Documents. 

3.38 Insurance. 
 (a)
Except as disclosed in Section 3.38(a) of the Disclosure Schedule, each insurable asset of each Group Company has at all material times been and is as of the date of this Agreement and the date of the Closing insured to its full replacement
value (with no provision for deduction or excess) against each risk normally insured against by a person operating the types of business operated by the relevant Group Company. 

(b) Except as disclosed in Section 3.38(b) of the Disclosure Schedule, each current insurance and indemnity policy in respect of which
each Group Company has an interest is valid and enforceable, and all premiums which are due and payable have been paid. 
 4. REPRESENTATIONS AND
WARRANTIES OF THE INVESTOR. The Investor hereby represents and warrants to the Group Companies, as of the date hereof, as follows: 

4.1 Authorization. The Investor has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to
which the Investor is a party, when executed and delivered by the Investor, will constitute valid and legally binding obligations of the Investor, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Shareholders’ Agreement may be limited by applicable U.S. federal, state or non-U.S. securities laws. 

  
 26 

 4.2 Disclosure of Information. The Investor has had an opportunity to discuss the
Group Companies’ business, management, financial affairs and the terms and conditions of the offering of the Shares with the Group Companies’ management. Nothing in this Section 4.2, including the foregoing sentence, limits or
modifies the representations and warranties of the Warrantors in Section 3 hereof or the right of the Investor to rely thereon or the remedies available to the Investor. 

5. CONDITIONS TO THE INVESTOR’S OBLIGATIONS AT CLOSING. The obligations of the Investor to purchase the Subscribed Shares at the Closing are
subject to the fulfillment to the satisfaction of the Investor, on or before the Closing, of each of the following conditions, unless otherwise waived in writing by the Investor: 

5.1 Representations and Warranties. The representations and warranties of the Warrantors contained in Section 3 hereof shall be
true and complete in all respects as of the Closing (or, if given as of a specific date, as of such date). 
 5.2 Performance. Each
Group Company, each Founder and each Founder Entity shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the
Closing. 
 5.3 Compliance Certificate. Mr. Zhang Tianze, a director of the Company, shall have delivered to the Investor at the
Closing a certificate certifying that the conditions specified in Section 5 hereof have been fulfilled. 
 5.4 Qualifications.
All authorizations, approvals or permits, if any, of any Governmental Authority or regulatory body that are required in connection with the lawful issuance and sale of the Subscribed Shares pursuant to this Agreement shall have been obtained and
effective as of the Closing. 
 5.5 Laws. The offer and sale of the Subscribed Shares to the Investor pursuant to this Agreement,
shall be exempt from the registration and prospectus delivery requirements of the Securities Act and shall not violate or breach or result in a violation or breach of any other applicable Laws. 

5.6 No Litigation; No Material Adverse Effect. No Action shall have been threatened or instituted against any Warrantor or the Investor
seeking to enjoin, challenge the validity of, or assert any Liability against any of them on account of, any transactions contemplated by this Agreement or the other Transaction Agreements. There shall not have occurred any Material Adverse Effect
or any events or circumstances which would reasonably be expected to result in a Material Adverse Effect. 
 5.7 Opinions of Company
Counsels. The Investor shall have received from the Company’s Cayman Islands counsel to be engaged prior to the Closing, an opinion dated as of the Closing, in a form reasonably satisfactory to the Investor. 

  
 27 

 5.8 Shareholders’ Agreement. Each Group Company and each other member of the
Company named as a party thereto (other than the Investor) shall have executed and delivered the Fifth Amended and Restated Shareholders’ Agreement to the Investor. 

5.9 Memorandum and Articles of Association. The Memorandum and Articles of Association shall have been duly adopted by the members of
the Company and shall become effective subject to and contingent as of the Closing. 
 5.10 Transaction Agreements. Each of the
parties to the Transaction Agreements, other than the Investor, shall have executed and delivered such Transaction Agreements to the Investor. 

5.11 Chairman’s Certificate. The chairman of the Board shall have delivered to the Investor at the Closing a certificate
certifying as to the truth and correctness as of the Closing of (a) the Memorandum and Articles of Association; (b) the resolutions of the Board approving the Memorandum and Articles of Association, the Transaction Agreements, and the
transactions provided for therein, and any other necessary matters; and (c) resolutions of the members of the Company approving the Memorandum and Articles of Association and any other necessary matters. 

5.12 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated by the Transaction
Agreements that are required to be completed on or before the Closing and all documents incident thereto shall have been completed as of the Closing and shall be reasonably satisfactory in form and substance to the Investor, whereby the pre-emptive
rights of the existing shareholders under the Section 4 of the Fourth Amended and Restated Shareholders’ Agreement shall have been duly waived, and the Investor (or its counsel) shall have received all certified or other copies of such
documents as reasonably requested. Such documents shall include a certificate of good standing certificate issued by the Registrar of Companies of the Cayman Islands, dated no earlier than thirty (30) Business Days prior to the date hereof.

 5.13 Confidential Information and Invention Assignment Agreements. On or prior to the Closing, each of the Founders and Key
Employees shall have entered into a confidential information and invention assignment agreement (which includes a non-compete provision) in the Company’s standard form to the satisfaction of the Investor. 

5.14 Due Diligence. The Investor shall have completed business, legal and financial due diligence investigation of the Group Companies
is satisfied with the due diligence results. 
 5.15 Business Cooperation. The Company shall have entered into a business cooperation
framework agreement (the “Business Cooperation Agreement”) with the Investor and/or its designated party, in the form and substance to this Agreement as Exhibit F, at least including the priority right of the Investor and/or
its designated party in cooperation with the Group Companies with respect to certain specific business. 
 5.16 Amendment to Series D
Purchase Agreement. The Company, the Investors (as defined in the Series D Purchase Agreement) and certain other parties named therein shall have entered into an Amendment to Series D Purchase Agreement, under which (i) Section 7.6 of
the Series D Purchase Agreement shall be deleted in its entirety and replaced with Section 7.6 hereof, (ii) Section 7.11(g) hereof shall be inserted into the Series D Purchase Agreement as Section 7.11(h),
(iii) Section 7.11(f) hereof shall be inserted into the Series D Purchase Agreement as Section 7.11(i), (iv) Section 7.15 of the Series D Purchase Agreement shall be deleted in its entirety and replaced with
Section 7.15 hereof, (v) Section 7.16 of the Series D Purchase Agreement shall be deleted in its entirety and replaced with Section 7.14 hereof, (vi) Section 7.20 of the Series D Purchase Agreement shall be deleted in
its entirety and replaced with Section 7.18 hereof (vii) Section 7.20 hereof shall be inserted into the Series D Purchase Agreement as Section 7.23, (viii) Section 7.21 hereof shall be inserted into the Series D
Purchase Agreement as Section 7.24, and (ix) Section 7.22 hereof shall be inserted into the Series D Purchase Agreement as Section 7.25. 

  
 28 

 5.17 Amendment to Series D+ Purchase Agreement I. The Company, the Investors (as
defined in the Series D+ Purchase Agreement I) and certain other parties named therein shall have entered into an Amendment to Series D+ Purchase Agreement I, under which (i) Section 7.1 of the Series D+ Purchase Agreement I shall be
deleted in its entirety and replaced with Section 7.1 hereof, (ii) Section 7.6 of the Series D+ Purchase Agreement I shall be deleted in its entirety and replaced with Section 7.6 hereof, (iii) Section 7.11(g) hereof
shall be inserted into the Series D+ Purchase Agreement I as Section 7.11(g), (iv) Section 7.11(f) hereof shall be inserted into the Series D+ Purchase Agreement I as Section 7.11(h), (v) Section 7.14 of the Series D+
Purchase Agreement I shall be deleted in its entirety and replaced with Section 7.14 hereof, (vi) Section 7.15 of the Series D+ Purchase Agreement I shall be deleted in its entirety and replaced with Section 7.15 hereof
(vii) Section 7.19 of the Series D+ Purchase Agreement I shall be deleted in its entirety and replaced with Section 7.18 hereof, (viii) Section 7.21 hereof shall be inserted into the Series D+ Purchase Agreement I as
Section 7.28, and (ix) Section 7.22 hereof shall be inserted into the Series D+ Purchase Agreement I as Section 7.29. 
 6. CONDITIONS TO
THE COMPANY’S OBLIGATIONS AT CLOSING. The obligations of the Company to sell the Subscribed Shares to the Investor at the Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions of the Investor,
unless otherwise waived in writing by the Company. 
 6.1 Representations and Warranties. The representations and warranties of the
Investor contained in Section 4 hereof shall be true and complete in all respects as of the Closing. 
 6.2 Performance. The
Investor shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 

6.3 Transaction Agreements. The Investor shall have executed and delivered the Shareholders’ Agreement and other Transaction
Agreements to which it is a party. 
  

	7.	 COVENANTS. 

7.1 Use of Proceeds. The Company will use the proceeds from the transactions contemplated by the Transaction Agreements (the
“Proceeds”) for and only for business expansion and working capital of the Group Companies in accordance with the budget and business plan approved pursuant to the Shareholders’ Agreement and the Memorandum and Articles of
Association, no such Proceeds shall be used (i) in the purchase of any securities, (ii) in the investment of any entities other than any Group Company, or (iii) in the repurchase or cancellation of securities held by any shareholders
of the Company. 

  
 29 

 7.2 Availability of Shares. The Company hereby covenants that at all times there
shall be made available, free of any encumbrances, for issuance and delivery upon conversion of the Subscribed Shares, such number of Ordinary Shares or other shares in the share capital of the Company as are from time to time issuable upon
conversion of the Subscribed Shares from time to time, and will take all steps necessary to increase its authorized share capital to provide for sufficient number of Ordinary Shares issuable upon conversion of the Subscribed Shares. 

7.3 Business of the Company and the HK Entity. The business of the Company shall be restricted to the holding of shares or equity
interest in the HK Entity. The business of the HK Entity shall be restricted to the holding of shares or equity interest in the WFOEs. 

7.4 Business Transfer. Upon the request of the Investor and subject to applicable Laws, the Domestic Company shall, and the Founders
shall cause the Domestic Company to, use best efforts to transfer its business as then conducted to the WFOEs in a tax and cost efficient way satisfactory to the Investor. 

7.5 Filing of the Memorandum and Articles of Association. The Company shall, and the Founders shall cause the Company to file the
Memorandum and Articles of Association with the Registrar of Companies of the Cayman Islands and provide a stamped copy of such fied Memorandum and Articles of Association to the Investor within fifteen (15) Business Days following the Closing.

 7.6 Compliance with Applicable Law. Each of the Group Companies shall, and the Key Founder shall cause each of the Group Companies
to, comply with all applicable Laws in all material aspects, including but not limited to applicable PRC Laws relating to privacy, medical records protection, telecommunication business, Intellectual Property, anti-monopoly, Tax, employment, and
social welfare and benefits, unless provided otherwise in Sections 7.11 and 7.12 (in which case, the Warrantors shall comply with provisions under those Sections and in the event of any Laws in relation to Sections 7.11 and 7.12 are promulgated, the
Group Companies shall, and the Founders shall procure the Group Companies to take all commercially reasonable efforts to comply with the requirements of such newly promulgated Laws, including without limitation, formulating and implementing any
proposals or plans according to the requirement by and advice from the sponsors and /or underwriters and the legal counsel engaged by the Company for the Company’s public offering of securities or the legal advice of the Company’s legal
counsel. If the compliance of such newly promulgated Laws may result in any change of the Group Companies’ major business, the Group Companies shall, and the Founders shall procure the Group Companies to report to the Board in a timely or
regular manner.), and obtain and maintain at all times all permits, licenses and any similar authority necessary for the conduct of its business. 

7.7 Insurance Coverage. Each of the Group Companies shall use its best efforts to obtain reasonably necessary insurance coverage to
protect its business, properties and personnel from potential risks in the daily operation of such Group Company, as determined by the Board (including the affirmative votes of the Preference Directors) in accordance with the Shareholders’
Agreement and the Memorandum and Articles. 

  
 30 

 7.8 Social Insurance, Housing Fund, Individual Income Tax, Value-Added Tax and Local
Levies, Corporate Income Tax and Other Applicable Taxes Compliance. The Founders and each Group Company in the PRC undertake that each such Group Company shall obtain a social insurance registration certificate as required by the PRC Law and
shall, following the Closing, fully comply with its obligations to (i) make all necessary social insurance contributions, (ii) make all necessary housing fund contributions, (iii) withhold and pay to the appropriate Governmental
Authorities all individual income tax required to be withheld from employees of each such Group Company, (iv) pay to the appropriate Governmental Authorities all the value-added taxes and related surcharges (collectively as “Value-Added
Tax and Local Levies”) required to be paid in connection with the products sold or services provided by each such Group Company, (v) pay to the appropriate Governmental Authorities all corporate income tax, (vi) pay to the
appropriate Governmental Authorities all other applicable Taxes, and (vii) promptly provide satisfactory evidence of the completion of the foregoing to the Investor upon request. Notwithstanding or concurrent with the foregoing, each Group
Company shall satisfy or set aside sufficient funds for all accrued but unpaid obligations with respect to Taxes, including but not limited to unpaid U.S. federal, state and local Tax obligations and unpaid PRC Tax obligations. 

7.9 Publicity. Without the prior written consent of the Investor, none of the Warrantors shall or shall cause any of its affiliates,
(a) use in advertising, publicity, announcements, or otherwise for any marketing, advertising or promotional purposes, the name of the Investor or any of its affiliates, either alone or in combination of, including but without limitation,
“阿里巴巴” (Chinese equivalent for “Alibaba”), “蚂蚁”(Chinese equivalent for “Ant”),
“蚂蚁金服”(Chinese equivalent for “Ant Financial”), “淘宝” (Chinese equivalent for “Taobao”), “ 阿里 “ (Chinese equivalent for “Ali”), “ 全球速卖通 “ (Chinese brand for “AliExpress”),”淘” (Chinese equivalent for “Tao”),
“天猫” (Chinese equivalent for “Tmall”), “优酷” (Chinese equivalent for “YOUKU”), “土豆” (Chinese equivalent for “TUDOU”), “阿里文学” (Chinese equivalent for “Alibaba Literature”), “ 一淘” (Chinese equivalent for “eTao”), “聚划算” (Chinese equivalent for “Juhuasuan”), “阿里妈妈” (Chinese equivalent for “Alimama”), “阿里云” (Chinese equivalent for “Aliyun”), “云OS” (Chinese equivalent for “YunOS”),
“万网” (Chinese brand for “HiChina”), “飞猪” (Chinese equivalent for “Fliggy’), “口碑” (Chinese equivalent for “Koubei’”), “虾米” (Chinese equivalent for “Xiami”), “余额宝” (Chinese equivalent for “Yu’e Bao”), “支付宝” (Chinese brand for “Alipay”), “小微金服” (Chinese equivalent for “Xiao Wei Jin Fu”), “1688”, “阿里通信” (Chinese equivalent for “AliTelecom”), “阿里健康” (Chinese equivalent for “AliHealth”), “九游” (Chinese equivalent for “9Game”), “钉钉” (Chinese equivalent for “Ding Talk”), “芝麻信用” (Chinese equivalent for “Zhima Credit”), “ 花呗” (Chinese equivalent for “HUABEI”), “ 网商银行” (Chinese equivalent for “MYbank”) “来往” (Chinese equivalent for “Laiwang”), “Alibaba”, Taobao”, “Ali”,
“AliExpress”, “Tao”, “Tmall”, “eTao”, “Juhuasuan”, “Alimama”, “Aliyun”, “YunOS”, “HiChina”, “Koubei”, “Xiami”, “Alipay”,
“Xiao Wei Jin Fu”, “Laiwang”, the associated devices and logos of the above brands (including but not limited to the smiling face device of Alibaba Group, the cow device of Alibaba.com, ant device of Taobao, Tao doll device of
Taobao, cat device of Tmall, Juxiaomeng device of Juhuasuan, lion device of Alipay and Zhixiaobao device of Alipay) or any company name, trade name, trademark, service mark, domain name, device, design, symbol or any abbreviation, contraction or
simulation thereof owned or used by the Investor or any of its affiliates, or (b) represent, directly or indirectly, that any products or services provided by any Group Company have been approved or endorsed by the Investor or any of its
affiliates. Each Group Company hereby grants the Investor or its affiliates license to use any Group Company’s company name, trade name, trademark, service mark, domain name, device, design and/or symbol in its respective marketing materials.
If the Investor or its affiliates have to use each Group Company’s company name, trade name, trademark, service mark, domain name, device, design and/or symbol, they must identify the rights held by each Group Company in relation to the company
name, trade name, trademark, service mark, domain name, device, design and/or symbol. The rights and obligations of each Warrantor under this Section 7.9 shall survive the termination of this Agreement. 

  
 31 

 7.10 Investor Nominee. The Group Companies and the Key Founder undertake to the
Investor that, upon request of the Investor after the Closing, (i) the Founders shall (and the Founders shall procure Peng TANG (汤鹏) to), as long as they hold any equity interest in the Domestic Company (collectively, the “Domestic Company Holders”), and the Warrantors shall cause the Domestic Company Holders
to, transfer on a pro rata basis in proportion to their respective equity interest in the Domestic Company for free to a nominee appointed by the Investor (the “Investor Nominee”) such percentage of the equity interest in the
Domestic Company beneficially held by the Domestic Company Holders that is equal to the percentage of the Company’s outstanding Ordinary Shares then held by the Investor on an as-converted basis, as soon as practicable and in any event within
thirty (30) Business Days upon request from the Investor, (ii) the Warrantors shall cause to be made any filing with the competent local office of Beijing Administration for Industry and Commerce to reflect the Investor Nominee’s
equity interest in the Domestic Company, (iii) the Warrantors shall cause to be delivered to the Investor the original copies of the updated articles of association, register of members and certificates of capital contribution of the Domestic
Company reflecting the foregoing transfer of equity interest of the Domestic Company. The Investor hereby covenants that, as long as the Investor Nominee appointed by it holds equity interest in the Domestic Company pursuant to this
Section 7.10, it shall (i) cause the Investor Nominee to execute and deliver the applicable Restructuring Documents in the form executed and delivered by other shareholders of the Domestic Company, (ii) in case its shareholding
percentage in the Company (on an as-converted basis) decreases after the acquisition of the equity interest of the Domestic Company by the Investor Nominee, cause the Investor Nominee to transfer such portion of the equity interest back to the
Domestic Company Holders for free to correctly reflect the decrease. The Warrantors shall cause the Domestic Company Holders, and the Investor shall cause its Investor Nominee (if any), to duly and punctually perform and observe this
Section 7.10. Without prejudicing the generality of the foregoing, the Warrantors shall cause the Domestic Company Holders, and the Investor shall cause its Investor Nominees (if any), (x) to amend the applicable Restructuring Documents to
reflect the change to the shareholding of the Domestic Company, and (y) to duly register the pledge of equity interest under the revised Restructuring Documents with the competent local office of Beijing Administration for Industry and
Commerce, in each case of (x) and (y), with the proof documents being delivered to the Investor, within three (3) months after the completion of the aforesaid transfer of equity interest. 

7.11 Business Contracts of the Group Companies. Unless agreed otherwise in writing by the Board (including affirmative votes of the
Preference Directors) in accordance with the Shareholders’ Agreement and the Memorandum and Articles, the Group Companies shall, and the Key Founder shall procure the Group Companies to, after the Closing: 

(a) use their commercially reasonable efforts to re-enter into the business contracts executed, and enter into any business contract to be
executed, with the hospital rather than any department or office of any hospital; 
 (b) amend the business contracts executed, and to be
executed, between any Group Company and a hospital (or any department or office of any hospital), in the form and substance to the reasonable satisfaction of the Investor, setting forth among others, (i) such Group Company is authorized by such
hospital to use any statistical and non-personally identifiable data processed from the medical records by such Group Company in accordance with applicable Laws and without infringement of the rights of such hospital and; (ii) such hospital
shall covenant to perform such business contract in compliance with all applicable Laws; and 

  
 32 

 (c) amend the business contracts executed between any Group Company and a pharmaceutical
company, in the form and substance to the reasonable satisfaction of the Investor, setting forth among others, such that in no event shall such Group Company’s Liability for any cause arising out of or related to such business contract, exceed
the fees paid by the pharmaceutical company to such Group Company under such business contract; 
 (d) use their best efforts to enter into
supplementary agreements with patients who have signed the receipts for “Discharged Patients Recovery Follow-up System”
(“出院患者康复随访系统”回执卡), and enter into an agreement with each and every patient from whom the Group Companies collect data, in the
form and substance to the reasonable satisfaction of the Investor, setting forth among others, such patient’s acknowledgment and agreement that the Group Companies are authorized to analyze, use, Process and commercialize the data collected
from such patient; 
 (e) use their best efforts to ensure that the agreements and documents between the hospitals and patients shall
include the patients’ consents and/or authorizations regarding the provisions of medical records by the hospitals to the Group Companies and the collection, analysis and Processing of medical records by the Group Companies; 

(f) take all necessary and desirable actions to ensure that the Qualified Medical Record Ratio shall be at least 75% by December 31,
2021, or if the foregoing is not reasonably practicable, use their best efforts to adopt and implement alternative measures related to collection and use of medical records by the Group Companies, as mutually agreed by the Company, on one hand, and
Series D+ Preference Majority (as defined in the Shareholders’ Agreement), on the other hand. For the purpose of this Agreement, “Qualified Medical Record Ratio” shall mean a fraction, the numerator of which is the aggregate
number of medical records that are collected by a Group Company pursuant to a duly executed agreement between a Group Company and a hospital (as a legal person recognized by PRC Law), authorizing the Group Companies further and recurrent commercial
use of the data in such medical records in a desensitized form; and the denominator of which is the aggregate number of all medical records collected or used by the Group Companies other than such medical records as agreed by the Company, on one
hand, and the Investor, on the other hand; and 
 (g) take all reasonably necessary actions to (i) improve the usage of medical data,
personal data and medical records in accordance with all applicable Laws, regulatory requirements of any competent authority, and recommendations proposed by the sponsors and /or underwriters and legal counsel engaged by the Company; (ii) solve
the compliance issues in the business conducted by the Group Companies, including but without limitation to, the patient recruitment in the Real World Study (“RWS”) business, the Direct to Patients (“DTP”) business
and online hospital in accordance with the recommendations proposed by the underwriter engaged by the Company; and (iii) improve the internal control systems related to the business as conducted or to be conducted by the Group Companies,
including but not limited to the business of RWS, DTP and online hospital in accordance with the recommendations proposed by the underwriter engaged by the Company. 

  
 33 

 7.12 Code of Data Classification Management and Conduct. The Group Companies shall,
and the Warrantors shall procure the Group Companies shall, operate their business in a way in compliance with the duly adopted internal Code of Data Classification Management and Conduct, and shall use their commercially reasonable efforts to
promote enactment of new legislations for more detailed rules, guidance or policies in relation to collection, process and commercialization of Internet healthcare data. 

7.13 Personal Data Processing and Privacy Protection. 

(a) Notwithstanding Section 7.11 hereof, following the date of Closing, the Group Companies shall and the Key Founder shall procure the
Group Companies to obtain and procure their Service Providers to obtain all rights, licenses, permissions, and consents from data subjects (including patients and hospitals) required by all applicable Laws to Process Personal Data and other
sensitive data to continue the business of any Group Company as presently conducted and as presently proposed to be conducted. The Group Companies shall and the Key Founder shall procure the Group Companies to ensure that following the date of
Closing, all of the Group Companies will be entitled to continue Processing Personal Data and other sensitive data that have been in their possession or under their control prior to the date of Closing, in compliance with all applicable Laws. 

(b) The Group Companies shall, and the Key Founder shall procure the Group Companies to, (i) protect the privacy of the patients and
protect Personal Data and other sensitive data from loss, theft, unauthorized access, misappropriation, modification, disclosure or other misuse, and (ii) comply with all applicable Laws and contractual obligations in all material aspects
related to Personal Data protection, information security, network security and protection of the privacy of the patients. Any use of the Personal Data and other sensitive data by the Group Companies and their Service Providers shall be in
compliance with all applicable Laws and contracts, to which any of such Group Companies is a party, in all material aspects. 
 (c) The
Group Companies shall (i) maintain a rigorous information security and privacy program that establishes reasonable and appropriate measures to protect the privacy, confidentiality, integrity and security of all Personal Data and other sensitive
data against any Security Breach, (ii) maintain a well-documented information security and privacy policy that fully and accurately describes how the Group Companies Process Personal Data and other sensitive data, and (iii) use reasonable
efforts to inform all employees, agents, contractors and consultants who Process Personal Data or other sensitive data for and on behalf of any the of Group Companies of the privacy and information security policies regarding the Processing of
Personal Data and other sensitive data, and ensure their compliance in all material aspects with such policies. 
 (d) If any of the Group
Companies commissions a third party to Process Personal Data or other sensitive data for and on its behalf, the Group Company shall and the Key Founder shall procure the Group Company to enter into written agreements that require the third party to
(i) take reasonable steps to protect and safeguard Personal Data and other sensitive data from loss, theft, unauthorized access, misappropriation, modification, disclosure or other misuse, (ii) retain Personal Data and other sensitive data
for only for a period that is reasonably required to satisfy the relevant business purposes, (iii) maintain a rigorous information security and privacy program that establishes reasonable and appropriate measures to protect the privacy,
confidentiality, integrity and security of all Personal Data and other sensitive data against any Security Breach, (iv) maintain a well-documented information security and privacy policy that fully and accurately describes how the third party
Processes Personal Data, and (v) comply at all times with applicable Laws in all material aspects. 

  
 34 

 7.14 Compliance with Restructuring Documents. The Warrantors shall ensure that each
party to the relevant Restructuring Documents fully perform its/his/her respective obligations thereunder and carry out the terms and the intent of the Restructuring Documents. For avoidance of doubt, subject to approval as required under the
Shareholders Agreement, the Restructuring Documents may be terminated, modified or waived according to the recommendations provided by the sponsors and /or underwriters engaged by the Company for the Company’s public offering of securities or
the legal advice of the Company’s legal counsel. 
 7.15 Tax Compliance and Indemnity. The Group Companies shall, and the
Warrantors shall procure the Group Companies, comply with all applicable tax Laws and regulations, including without limitation, laws and regulations pertaining to income tax and value added tax, and enhance the internal tax control of the Group
Companies according to the proposal provided by the tax counsel of the Group Company. Without limiting the generality of the foregoing, the Group Companies shall, and the Warrantors shall procure the Group Companies improve the tax compliance in all
aspects according to the recommendations provided by the sponsors and /or underwriters engaged by the Company for the Company’s public offering of securities, and the auditors of the Company, as well as in accordance with the proposal provided
by the tax counsel of the Group Company. The Warrantors shall jointly and severally indemnify the Investor against any and all losses, Liabilities, damages, suits, obligations, judgments or settlements or any kind (including, without limitation, all
reasonable legal costs, costs of recovery and other expenses incurred) resulting from any claim of Taxes (including, without limitation, those resulting from cancellation or reclamation of Tax benefits of any kind relating to the Group Companies,
any Taxes, Tax penalties and late payment interests) arising from an event that occurred or is deemed to have occurred prior to the Closing. 

7.16 Capital Contribution of the WFOE I. Notwithstanding any other provision to the contrary in any Transaction Agreement, the Company
shall inject substantially all of the Subscription Price into the registered capital of the WFOE I (the “WFOE Capital Injection Amount”). Each of the Warrantors, jointly and severally, agrees that (i) in the event of a
subsequent sale of Shares in the Company by the Investor, the Investor shall be entitled to apply the pro rata portion of the WFOE Capital Injection Amount to the Investor’s indirect basis in the equity (or equity cost) of the WFOE I with
respect to any Tax filing, Tax position and other communication with the relevant PRC Tax authorities for purposes of determining any income tax, capital gains tax or any other Tax calculated with reference to gains made through the subscription,
purchase and sale of the Company’s Shares, and (ii) it shall use its commercially reasonable efforts to not take any position that is inconsistent with (or would otherwise adversely impact the credibility of) clause (i) above in its
filings or other communications with the relevant PRC Tax authorities. Notwithstanding anything to the contrary herein, the Company shall indemnify the Investor against all Taxes or duties, in connection with the Investor’s sale of its
respective Subscribed Shares, levied on the Investor by the relevant PRC Tax authorities as the result of the Tax base for such Subscribed Shares determined by the relevant PRC Tax authorities being less than the Investor’s applicable
subscription price set forth opposite the Investor’s name in Schedule B attached hereto for such Subscribed Shares due to the Company’s failure to inject the WFOE Capital Injection Amount into the registered capital of the WFOE I.

  
 35 

 7.17 Further Assurances. Upon the terms and subject to the conditions herein, each of
the Parties hereto agrees to use its reasonable best efforts to take or cause to be taken all action, to do or cause to be done, to execute such further instruments, and to assist and cooperate with the other Parties hereto in doing, all things
necessary, proper or advisable under applicable Laws or otherwise to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement and the other Transaction Agreements, provided
that except as expressly provided herein, no Party shall be obligated to grant any waiver of any condition or other waiver hereunder. 

7.18 Filing of Lease Agreements. As soon as practicable after the Closing, and in any event no later than the date as approved by the
Board (including the affirmative votes of the Preference Directors) in accordance with the Shareholders’ Agreement and the Memorandum and Articles, the Company and the Founders shall use commercially reasonable efforts to file the lease
agreements of any Group Company with the relevant real property administration authorities in the PRC. 
 7.19 Patient Follow-up. The
Group Companies shall, and the Key Founder shall procure the Group Companies to, take all necessary and desirable actions to ensure that as of the date of the Closing and at any time thereafter, at least 80% of the patients followed-up shall have
given their informed consent to the Group Companies for further and recurrent commercial use of the personal data collected from such patients, in each case, in accordance with applicable PRC Laws (either by executed consent form or verbal
confirmation on a recorded call between the Group Companies’ representatives and such patients). For the purpose of this Section 7.19, “patients followed-up” shall mean patients who have received at least one successful follow-up
interviews by representatives of the Group Companies since the date hereof. 
 7.20 Online Publishing Service License. As soon as
practicable after the Closing, Kuaima Subsidiary shall, and the other Warrantors shall cause Kuaima Subsidiary to, apply for and obtain the Online Publishing Service License
(“网络出版服务许可证” in Chinese) in respect of the business of
Kuaima Subsidiary from the competent Governmental Authority. 
 7.21 Anti-Corruption. Subject to PRC Decree 1, the Warrantors
shall continue to comply with all applicable anti-bribery or anti-corruption Laws, including but not limited to the U.S. Foreign Corrupt Practices Act, the United Kingdom Bribery Act, the People’s Republic of China Criminal Law, the
People’s Republic of China Anti-Unfair Competition Law, or any other, in each cases as amended from time to time, and in no event will the Warrantors accept or will the Company Representatives accept any Prohibited Payment. Subject to PRC
Decree 1, the Warrantors shall not and shall procure any of the Group’s respective administrators, officers or the Founders not make any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or receive or retain
any funds in violation of any applicable Laws subject to applicable exceptions and affirmative defenses. The Warrantors shall establish an internal compliance regulatory system in this regard within three (3) months after the Closing and
strictly implement such system in the ordinary business operation. The Warrantors shall fill in the compliance questionnaire provided by the Investor in a true, accurate and comprehensive manner and submit it in due course. 

  
 36 

 7.22 Internal System. The Group Companies shall have established and maintained the
accounting policies and financial system in full compliance with all applicable Laws and regulations and to the satisfaction of the Company’s auditor, and shall improve the internal accounting and financial management in accordance with the
applicable Laws, the regulatory requirements and recommendations provided by the sponsors and /or underwriters engaged by the Company for the Company’s public offering of securities, the Company’s auditor and the Investor. Within six
(6) months after the Closing, (a) the Company shall engage a tax counsel and a legal counsel to provide a proposal to enhance the internal tax control and legal compliance of the Group Companies for purpose of the consummation of a
Qualified IPO, taking into consideration of the main issues raised by the Investor, and shall update Ali Director or Ali Observer with such proposal in a prompt manner; and (b) the Group Companies shall use their reasonable efforts to rectify
non-compliance issues in accordance with the such proposal. The Company shall, and the Warrantors shall procure the Company to, use its commercially reasonable efforts to involve Ali Director or Ali Observer in the discussions of such proposal and
communicate with Ali Director or Ali Observer regarding the implementation of such proposal. 
 7.23 Indemnification Agreement. In
the event that the Investor does not appoint any person to serve as Ali Director immediately upon the Closing, and elects to appoint a person designated as Ali Director pursuant to Section 6.1(f) of the Shareholders’ Agreement at any time
after the Closing, the Company shall, and the Warrantors shall procure the Company, upon the written notice by the Investor to the Company to appoint the person designated as Ali Director, enter into the Indemnification Agreement with the Investor
and Ali Director, in the form as attached to this Agreement as Exhibit E. 
 7.24 Budget. As soon as practicable after the
Closing, but in no event later than March 30, 2021, the Company shall provide a financial budget of the Group Companies to the Investor in reasonable details for the next twelve (12) months from the Closing. 

7.25 Additional Covenants. 

(a) Except as required by this Agreement or contemplated by other Transaction Agreements, between the date of this Agreement and the Closing,
each of the Group Companies shall (and the Warrantors shall cause each of the Group Companies to) (i) conduct its business in the ordinary course consistent with past practice, as a going concern and in compliance with all applicable Laws and
contracts and agreements in material aspects, (ii) pay or perform its debts, Taxes, and other obligations when due, (iii) maintain its assets in a condition comparable to their current condition, reasonable wear, tear and depreciation
excepted, (iv) use reasonable best efforts to preserve intact its current business organizations and keep available the services of its current officers and employees and preserve its relationships with customers, suppliers and others having
business dealings with it, (v) otherwise periodically report to the Investor concerning the status of its business, operations and finance, and (vi) take all actions reasonably necessary, to consummate the transactions contemplated by this
Agreement promptly, including the taking of all reasonable acts necessary to cause all of the conditions precedent of the Investor to be satisfied. 

(b) Except as required by this Agreement or contemplated by other Transaction Agreements, between the date of this Agreement and the Closing,
none of the Group Companies shall (and the Warrantors shall not permit any of the Group Companies to) (i) take any action that would make any representation and warranty of the Company inaccurate at the Closing, (ii) waive, release or
assign any material right or claim, (iii) take any action that would reasonably be expected to materially impair the value of the Group Companies, (iv) sell, purchase, assign, lease, transfer, pledge, encumber or otherwise dispose of any
material asset, (v) issue, sell, or grant any equity security unless otherwise pursuant to the Transaction Agreements, (vi) declare, issue, make, or pay any dividend or other distribution with respect to any Equity Security,
(vii) incur any indebtedness for borrowed money or capital lease commitments or assume or guarantee any indebtedness of any Person unless otherwise pursuant to the Transaction Agreements, or (viii) authorize, approve or agree to any of the
foregoing. If at any time before the Closing, any of the Warrantors comes to know of any material fact or event which: 

  
 37 

 (1) is in any way materially inconsistent with any of the representations and warranties
given by each Warrantor, subject to any qualification by the Disclosure Schedule, 
 (2) suggests that any material fact warranted may not
be as warranted or may be materially misleading, or 
 (3) might affect the willingness of a reasonable investor in making a prudent
decision to purchase the Subscribed Shares or the amount of consideration which the Investor would be prepared to pay for the Subscribed Shares, 
 such
Warrantor shall give immediate written notice thereof to the Investor in which event the Investor may within five (5) Business Days of receiving such notice terminate this Agreement by written notice without any penalty whatsoever and without
prejudice to any rights that the Investor may have under this Agreement or applicable Law, provided, that, if (i) the event described in (1), (2) or (3) above would not, result or reasonably be expected to result, in a Material
Adverse Effect, and (ii) in each case such event is curable within reasonable period time, then this Agreement may not be terminated under this Section 7.24. If this Agreement is terminated in the event of (1) or (2) above, or in
the event of (3) above when such fact or event is caused by the Company, solely in the event of fraud or gross negligence by any Warrantor, each Warrantor shall jointly and severally indemnify the Investor against all costs, charges and
expenses incurred by it in connection with the negotiation, preparation and termination of the Transaction Agreements. 
 7.26
Reclassification of Ordinary Shares. In the event the Company proposes to reclassify its Ordinary Shares into class A ordinary shares (each with one vote) and class B ordinary shares (each with no more than ten vetos) prior to IPO, under
which reclassification, all of the outstanding Ordinary Shares held by the Founders will be reclassified as the class B ordinary shares and the Ordinary Shares reserved for issuance upon conversion of the Preference Shares held by the Investor and
other holders of the Preference Shares and all other authorized Ordinary Shares will be reclassified as class A ordinary shares, and the aforesaid proposal is submitted for the approval of the resolutions of shareholders of the Company or the board
of the Company, Ali shall, and Ali shall procure Ali Director (if any) to, vote in favor of such reclassification proposal, subject to the requisite approval by the other shareholders and directors of the Company. 

 

	8.	 CURE OF BREACHES; INDEMNITY. 

8.1 Irrespective of any information available to or knowledge of the Investor, in the event of: (a) any breach or violation of, or
inaccuracy or misrepresentation in, any representation or warranty made by the Warrantors contained herein or any of the other Transaction Agreements; (b) any breach or violation by the Warrantors of any covenant or agreement contained herein
or any of the other Transaction Agreements; (c) any breach or non-performance by the Company of its obligations under the Memorandum and Articles of Association; or (d) any regulatory or law enforcement action by any applicable regulators
or law enforcement authority against any of the Group Company in connection with the matters resulting in the Founders and the Group Companies being required to make the payments under Section 8.1 herein (each of (a), (b), (c) or (d), a
“Breach”), the Warrantors shall cure such Breach (to the extent that such Breach is curable) to the satisfaction of the Investor. Notwithstanding the foregoing, the Warrantors shall also, jointly and severally, indemnify the
Investor and its Affiliates, limited partners, members, stockholders, employees, agents, representatives, assignees and transferees (each, an “Indemnitee”) for any and all losses, Liabilities, damages, Liens, claims, obligations,
penalties, settlements, deficiencies, costs and expenses, including without limitation reasonable advisor’s fees and other reasonable expenses of investigation, defense and resolution of any Breach paid, suffered, sustained or incurred by the
Indemnitees resulting from, or arising out of, or due to, directly or indirectly, any Breach (each individually an “Indemnifiable Loss,” and collectively the “Indemnifiable Losses”). 

  
 38 

 8.2 Subject to Section 8.5 hereunder, the rights to indemnification set forth in this
Section 8 are in addition to, and not in limitation of, all rights and remedies to which the Investor may be entitled including without limitation specific performance. 

8.3 Notwithstanding any other provision herein and notwithstanding whether or not as disclosed in the Disclosure Schedule, the Warrantors
shall, jointly and severally, indemnify and keep indemnified the Indemnitees and hold them harmless against any and all Indemnifiable Losses resulting from, or arising out of, or in connection with, or due to, directly, (i) any claim for Tax
which has been made or may hereafter be made against any Group Company wholly or partly in respect of or in consequence of any event (including without limitation any restructuring) occurring (whether before, on or after the Closing) or any income,
profits or gains earned, accrued or received by any Group Company on or before or after the Closing and any reasonable costs, fees or expenses incurred and other Liabilities which any Group Company may properly incur in connection with the
investigation, assessment or the contesting of any claim, the settlement of any claim for Tax, any legal proceedings in which any Group Company claims in respect of the claim for Tax and in which an arbitration award or judgment is given for any
Group Company and the enforcement of any such arbitration award or judgment whether or not such Tax is chargeable against or attributable to any other Person; provided, however, that the Warrantors shall be under no Liability in respect of
Taxes that is promptly cured and without any material adverse effect to the Investor; or to the extent that the Liability arises as a result only of a provision or reserve in respect of the Liability made being insufficient by reason of any increase
in rates of Tax announced after the Closing with retrospective effect; (ii) any absence or deficiency in its payment of social insurance contributions and/or housing fund by any Group Company for its staff members, whether such absence or
deficiency occurring before or after the Closing; (iii) any failure by any Warrantor to comply with any applicable Laws regarding the administration of medical records of the patients, excluding the PRC Entity(ies) has entered into certain
business contracts with the departments or offices of the hospitals rather than hospitals (the foregoing matter shall be corrected pursuant to Section 7.11 hereof); (iv) notwithstanding anything to the contrary, any failure to obtain the
approvals from the patients, hospitals, doctors from whom the Group Companies collected, processed and used the medical records before or/and after the Closing, in the event of any breach or violation by the Group Companies and the Key Founder of
any covenant or agreement contained in Section 7.12, (v) any leak of the data from the medical records or other information collected, processed and/or used by the Group Companies which has a Material Adverse Effect, and/or (vi) any
breach or violation by the Group Companies and the Key Founder of any covenant or agreement contained in Section 7.11 and/or 7.13. 

  
 39 

 8.4 If the Investor or other Indemnitee believes that it has a claim that may give rise to
an obligation of any Warrantor pursuant to this Section 8, it shall give reasonably prompt notice thereof to the Warrantors stating specifically the basis on which such claim is being made, the material facts related thereto, and the amount of
the claim asserted. In the event of a third party claim against an Indemnitee for which such Indemnitee seeks indemnification from the Warrantors pursuant to this Section 8, no settlement shall be deemed conclusive with respect to whether there
was an Indemnifiable Loss or the amount of such Indemnifiable Loss unless such settlement is consented to by one Warrantor acting on behalf of the other Warrantors, which consent shall not be unreasonably withheld. Any dispute related to this
Section 8 shall be resolved pursuant to Section 9.16 hereof. 
 8.5 Notwithstanding anything to the contrary herein, 

(a) the maximum aggregate monetary Liability of the Founders and the Founder Entities towards the Investor and its respective Indemnitees
under this Agreement shall be limited to the applicable Subscription Price actually paid by the Investor, as the case may be; 
 (b) only if
any of the Founders and his or her Founder Entity is absent of fraud, intentional misrepresentation or willful misconduct by them, such Founder or his or her Founder Entity may elect to satisfy the entirety of their obligations under this
Section 8 by transferring the Ordinary Shares of the Company in whole or in part directly or indirectly held by them to the Indemnitee(s) at no consideration. If such Founder and its Founder Entity elect to satisfy their entire obligations
under this Section 8 pursuant to the foregoing paragraph under this Section 8.5(b) by transferring the Ordinary Shares of the Company to the Indemnitee(s) at no consideration, in no event shall the assets of such Founder and the Founder
Entity (other than the Ordinary Shares of the Company directly or indirectly held by them) be used to indemnify any Indemnifiable Losses of the Indemnitee(s). In computing the number of such Ordinary Shares to be transferred hereunder, the value of
such Ordinary Shares shall be the fair market value thereof at the time of the indemnification claim as determined in good faith by the Board (including the affirmative votes of the Preference Directors) in accordance with the Shareholders’
Agreement and the Memorandum and Articles; 
 (c) the Founders (other than the Key Founder) shall not be liable, either severally or jointly
with the Key Founder or any Group Company, solely for any breach of or non-compliance with any provisions under Sections 7.6, 7.11, 7.12, 7.13 and 7.17 by the Key Founder and/or any Group Companies or any Indemnifiable Losses under
Section 8.3(iii) to Section 8.3(vi). 
  

	9.	 GENERAL PROVISIONS. 

9.1 Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Group Companies and
the Investor contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on
behalf of the Investor or the Group Companies. 
 9.2 FIRPTA Notice. The Company shall provide prompt notice to the Investor
following any “determination date” (as defined in Section 1.897-2(c)(1) of the Regulations) on which the Company becomes a United States real property holding corporation. In addition, upon a written request by the Investor, the
Company shall provide the Investor with a written statement informing the Investor whether its interest in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements of
Section 1.897-2(h)(1) of the Regulations or any successor regulation, and the Company shall provide timely notice to the United States Internal Revenue Service, in accordance with and to the extent required by Section 1.897-2(h)(2) of the
Regulations or any successor regulation, that such statement has been made. The Company’s written statement to the Investor shall be delivered to the Investor within ten (10) days of the Investor’s written request therefor. The
Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class of the Company’s shares may be regularly traded on an established securities market or the fact that there is no preference share
then outstanding. 

  
 40 

 9.3 Successors and Assigns. The provisions hereof shall inure to the benefit of, and
be binding upon, the successors, permitted assigns, heirs, executors and administrators of the Parties hereto whose rights or obligations hereunder are affected by such amendments. This Agreement and the rights and obligations herein may be assigned
by the Investor to any Affiliate of the Investor. This Agreement and the rights and obligations therein may not be assigned by any Warrantor without the prior written consent of the Investor. 

9.4 Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any Person, other than the parties hereto
and their permitted successors and assigns, any rights or remedies under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.5 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the internal Laws of Hong Kong
as such Laws are applied to agreements between Hong Kong residents entered into and to be performed within Hong Kong. 
 9.6
Counterparts; Facsimile. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. A
facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such
party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. 
 9.7 Interpretation;
Titles and Subtitles. This Agreement shall be construed according to its fair language. The rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in interpreting this Agreement.
The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

9.8 Notices. Except as may be otherwise provided herein, all notices and other communications given, delivered or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given, delivered or made upon the earliest of actual receipt of: (a) personal delivery to the party to be notified, (b) when sent, if sent by email or facsimile during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, or (c) one (1) Business Day after deposit with an internationally-recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses, facsimile numbers or emails as set forth on Schedule F. If no facsimile number or
email is listed for a party, notices and communications given, delivered or made by facsimile or email, as the case may be, shall not be deemed effectively given, delivered or made to such party. If a notice or other communication is sent via an
approach other than email, a copy of such notice shall be sent via email to the recipient. 

  
 41 

 A party may change or supplement the addresses given above, or designate additional
addresses, for purposes of this Section 9.8, by giving the other parties written notice of the new address in the manner set forth above. 

9.9 No Finder’s Fees. Except as disclosed in the Disclosure Schedule, each party represents that it neither is nor will be
obligated for any finder’s fee or commission in connection with this transaction. The Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Investor or any of its officers, employees, or representatives is responsible. The Company agrees
to indemnify and hold harmless the Investor from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability
or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
 9.10 Fees and
Expenses. Unless otherwise stated in this Agreement, each Party shall pay all of its own costs, expenses and any Tax of any nature that is required by any applicable Laws to be paid by such Party incurred in connection with the negotiation,
execution, delivery and performance of this Agreement and other Transaction Agreements and the transactions contemplated hereby and thereby. If the Closing occurs, or fails to occur for any reasons that is not attributable to the Investor, the
Company shall promptly pay or reimburse all expenses and costs of counsel, accountants, consultants, and other advisors to the Investor in connection with the due diligence exercises and the negotiation, execution, delivery and performance of this
Agreement and other Transaction Agreements and the transactions contemplated hereby and thereby within ten (10) Business Days after the earlier of (x) the Closing or (y) the termination date of this Agreement, up to a maximum of
US$400,000. The Warrantors acknowledge that the Transaction Agreements will not be executed in, or brought into, the Cayman Islands, and there are no stamp duties, income taxes, withholdings, levies, registration taxes, or other duties or similar
Taxes or charges now imposed, or which under the present Laws of the Cayman Islands could in the future become imposed, in connection with (i) the execution and delivery of the Transaction Agreements, (ii) the enforcement or admissibility
in evidence of the Transaction Agreements, (iii) the issuance by the Company of the Series D+ Preference Shares or the issuance of the Conversion Shares, or (iv) on any payment to be made by the Company, the Investor or any other person
pursuant to the Transaction Agreements. 
 9.11 Amendments and Waivers. Prior to the Closing, this Agreement may be amended only with
the prior written consent of each party hereto. Following the Closing, any term of this Agreement may be amended, terminated or waived only with the written consent of the Company and the Investor. Any amendment or waiver effected in accordance with
this Section 9.11 shall be binding upon the Investor and each transferee of the Shares (or the Ordinary Shares issuable upon conversion thereof), each future holder of all such securities, and the Company. 

9.12 Severability. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not
affect the remaining provisions of this Agreement. 
 9.13 Delays or Omissions. No delay or omission to exercise any right, power or
remedy accruing to any party upon any breach or default of any other party hereto under this Agreement, shall impair any such right, power or remedy of the aggrieved party nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of
any party of any breach or default under this Agreement or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement, or by Law or otherwise afforded to the parties shall be cumulative and not alternative. 

  
 42 

 9.14 Entire Agreement. This Agreement, the Memorandum and Articles of Association,
the other Transaction Agreements and the schedules and exhibits hereto and thereto, which are hereby expressly incorporated herein by this reference, constitute the entire understanding and agreement between the parties with regard to the subjects
hereof and thereof; provided, however, that nothing in this Agreement or related agreements shall be deemed to terminate or supersede the provisions of confidentiality and non-disclosure agreements entered into prior to the date of
this Agreement, and such confidentiality and non-disclosure agreements shall continue in full force and effect until terminated in accordance with its terms contained therein. 

9.15 Pronouns. All pronouns and any variations thereof are deemed to refer to the masculine, feminine, neuter, singular or plural, as
the identity of the Person or Persons may require. 
 9.16 Dispute Resolution. 

(a) Negotiation Between Parties; Mediations. The parties agree to negotiate in good faith to resolve any dispute between them regarding
this Agreement. If the negotiations do not resolve the dispute to the reasonable satisfaction of the relevant parties, then each party to the dispute that is a company shall nominate one (1) authorized officer as its representative. The
relevant parties or their representatives, as the case may be, shall, within thirty (30) days of a written request by either party to call such a meeting, meet in person and alone (except for one (1) assistant for each party) and shall
attempt in good faith to resolve the dispute. If the disputes cannot be resolved by such senior managers in such meeting, the parties agree that they shall, if requested in writing by either party, meet within thirty (30) days after such
written notification for one (1) day with an impartial mediator and consider dispute resolution alternatives other than formal arbitration. If an alternative method of dispute resolution is not agreed upon within thirty (30) days after the
one (1) day mediation, either party to the dispute may begin formal arbitration proceedings to be conducted in accordance with Section 9.16(b) hereof. This procedure shall be a prerequisite before taking any additional action hereunder.

 (b) Arbitration. In the event the parties are unable to settle a dispute between them regarding this Agreement in accordance with
Section 9.16(a) hereof, such dispute shall be referred to and finally settled by arbitration in Hong Kong at the Hong Kong International Arbitration Centre in accordance with Hong Kong International Arbitration Centre Administered Arbitration
Rules (the “HKIAC Rules”) in effect, which rules are deemed to be incorporated by reference into this Section 9.16(b), subject to the following: (i) the arbitration tribunal shall consist of three (3) arbitrators to
be appointed according to the HKIAC Rules; and (ii) the language of the arbitration shall be English. The award of the arbitral tribunal shall be final and binding upon the parties thereto, and the prevailing party may apply to a court of
competent jurisdiction for enforcement of such award. Notwithstanding anything in this Agreement or in the HKIAC Rules or otherwise, the arbitration tribunal shall not have the power to award injunctive relief or any other equitable remedy of any
kind against the Investor unless such award both (x) is expressly appealable to and subject to de novo review by the courts of Hong Kong, and (y) would not, if upheld, have the effect of impairing, restricting, or imposing any
conditions on the right or ability of the Investor or any of its Affiliates to conduct its respective business operations or to make or dispose of any other investments. The prevailing party shall be entitled to reasonable attorney’s fees,
costs and necessary disbursements in addition to any other relief to which such party may be entitled. During the course of the arbitral tribunal’s adjudication of the dispute, this Agreement shall continue to be performed except with respect
to the part in dispute and under adjudication. 

  
 43 

 9.17 No Commitment for Additional Financing. The Company acknowledges and agrees that
the Investor has not made and will not make any representation, undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than the purchase of the Subscribed Shares as set
forth herein and subject to the conditions set forth herein. In addition, the Company acknowledges and agrees that (a) no statements, whether written or oral, made by the Investor or its representatives on or after the date of this Agreement
shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment, (b) the Company shall not rely on any such statement by the Investor or its representatives and (c) an
obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment may only be created by a written agreement, signed by the Investor and the Company, setting forth the terms and conditions of such
financing or investment and stating that the parties intend for such writing to be a binding obligation or agreement. The Investor shall have the right, in its sole and absolute discretion, to refuse or decline to participate in any other financing
of or investment in the Company, and shall have no obligation to assist or cooperate with the Company in obtaining any financing, investment or other assistance. 

9.18 No Negotiation. From the date of this Agreement until the Closing, the Group Companies and the Founders shall deal exclusively
with the Investor in connection with any investment in any Group Company or the purchase of any assets from any Group Company, and shall not, and shall cause their respective Affiliates and any Person acting on behalf of them or any of their
Affiliates not to, directly or indirectly solicit, initiate, encourage or entertain any inquiries or proposals from, discuss or negotiate with, provide any non-public information to or consider the merits of any inquiries or proposals from any
Person (other than the Investor) relating to the transactions contemplated by this Agreement or any business combination transaction involving any Group Company, including the sale of shares (including in trust), the merger or consolidation of any
Group Company, or the sale of all or any material portion of any Group Company’s business or assets, or the license of any material Intellectual Property of any Group Company, or any comparable transaction or other transaction that would be
inconsistent with the transactions contemplated by this Agreement. From the date of this Agreement until the Closing, the Group Companies and the Founders shall notify the Investor of any such inquiry or proposal promptly upon receipt or awareness
of the same, or the solicitation or initiation any such inquiry or proposal, by any Group Company, Founders, their respective Affiliates, or any Person acting on their behalf. 

9.19 Exclusivity. Each Warrantor hereby agrees that, unless otherwise agreed by the Investor, from the date hereof until (i) the
Closing or (ii) the date of the termination of the Agreement, which is earlier, neither the Warrantor nor any of its representative or agent shall directly or indirectly initiate, respond to, or participate in any discussions regarding, or
accept any proposal for, any equity or debt financing or sale of any of the Group Companies or their Subsidiaries, unless with the prior written consent of the Investor. 

  
 44 

 9.20 Termination. This Agreement may be terminated prior to the Closing (i) by
mutual written consent of the Parties, (ii) by the Company with respect to the Investor by written notice to the Investor if there has been a material breach or violation of a representation, warranty, covenant or agreement contained in this
Agreement on the part of the Investor, and such breach, if curable, has not been cured within fourteen (14) days of such notice, (iii) by the Investor by written notice to any of the Warrantors, if there has been a material breach or
violation of a representation, warranty, covenant or agreement contained in this Agreement on the part of any of the Warrantors, and such breach, if curable, has not been cured within fourteen (14) days of such notice, or (iv) by the
Investor, or by the Company, in each case, if the Closing fails to occur within ten (10) Business Days after the date hereof, provided that (i) the right to terminate this Agreement under this Section 9.20 shall not be available to
any Party if the failure of such Party to fulfill or breach by such Party of any obligation under this Agreement has been the cause of, or resulted in, the failure of the Closing to occur on or before such date. If this Agreement is terminated by
any Party pursuant to this Section 9.20, this Agreement will be of no further force or effect with respect to such Party terminating this Agreement, provided that the termination does not affect such Party’s accrued rights and
obligations as of such termination, provided, further, that, any such termination shall not affect the rights and obligations of any Party that has not terminated this Agreement (including the Investor’s right to consummate the
transactions contemplated herein to the extent the Investor has not terminated this Agreement pursuant to this Section 9.20). 

[SIGNATURE PAGES FOLLOW] 

  
 45 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“COMPANY”
	
	LinkDoc Technology Limited
		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Director
	
	“HK ENTITY”
	
	 LinkDoc Technology HK Limited

(零氪科技香港有限公司)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Director
	
	“DOMESTIC COMPANY”
	
	 Ling Ke Technology (Beijing) Co., Ltd.

(零氪科技(北京)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“WFOE I”
	
	 Ling Ke Information Technology (Beijing) Co., Ltd.

(零氪信息技术(北京)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“TIANJIN SUBSIDIARY I”
	
	 Ling Ke Technology (Tianjin) Co., Ltd.

(零氪科技(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“GUANGZHOU SUBSIDIARY”
	
	 Ling Ke Medical Intelligent Technology (Guangzhou) Co., Ltd.

(零氪医疗智能科技(广州
)有限公司) (seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative
	
	“NINGXIA SUBSIDIARY”
	
	 Yinchuan Ling Ke Medical Internet Co., Ltd.

(银川零氪互联网医院有限公司)
(seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“REAL WORLD”
	
	 Real World Medical Technology (Beijing) Co., Ltd.

(瑞尔沃德医药科技(北京
)有限公司) (seal)

		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“TIANJIN SUBSIDIARY I”
	
	 Ling Ke Technology (Tianjin) Co., Ltd.

(零氪科技(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“GUANGZHOU SUBSIDIARY”
	
	 Ling Ke Medical Intelligent Technology (Guangzhou) Co., Ltd.

(零氪医疗智能科技(广州
)有限公司) (seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative
	
	“NINGXIA SUBSIDIARY”
	
	 YINCHUAN Ling Ke Medical Internet Co., Ltd.

(银川零氪互联网医院有限公司)
(seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“REAL WORLD”
	
	 Real World Medical Technology (Beijing) Co., Ltd.

(瑞尔沃德医药科技(北京
)有限公司) (seal)

		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“WFOE II”
	
	 Ling Ke Investment (Tianjin) Co., Ltd.

(零氪投资(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“JV ENTITY”
	
	 Ling Ke Medical Technology (Tianjin) Co., Ltd.

(零氪医疗科技(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“Kuaima Subsidiary”
	
	 Beijing Kuaima Hulian Technology Co., Ltd.

(北京快马互联科技有限公司)
(seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“WFOE II”
	
	 Ling Ke Investment (Tianjin) Co., Ltd.

(零氪投资(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“JV ENTITY”
	
	 Ling Ke Medical Technology (Tianjin) Co., Ltd.

(零氪医疗科技(天津)有限公司) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative
	
	“Kuaima Subsidiary”
	
	 Beijing Kuaima Hulian Technology Co., Ltd.

(北京快马互联科技有限公司)
(seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“TIANJIN SUBSIDIARY II”
	
	 Ling Ke Intelligent Medical Technology (Tianjin) Co., Ltd.

(零氪智慧医疗科技(天津
)有限公司) (seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative
	
	“LINGBO SUBSIDIARY”
	
	 Lingbo (Beijing) Medical Technology (Tianjin) Co., Ltd.

(领博(北京)医疗科技有限公司
) (seal)

		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Legal Representative
	
	“LINGCE SUBSIDIARY”
	
	 Beijing Lingce Smart Technology Center (Limited Partnership)

(北京领策智能科技中心(有限合伙
)) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“TIANJIN SUBSIDIARY II”
	
	 Ling Ke Intelligent Medical Technology (Tianjin) Co., Ltd.

(零氪智慧医疗科技(天津
)有限公司) (seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative
	
	“LINGBO SUBSIDIARY”
	
	 Lingbo (Beijing) Medical Technology Co., Ltd.

(领博(北京)医疗科技有限公司
) (seal)

		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Legal Representative
	
	“LINGCE SUBSIDIARY”
	
	 Beijing Lingce Smart Technology Center (Limited Partnership)

(北京领策智能科技中心(有限合伙
)) (seal)

		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“HEBEI SUBSIDIARY”
	
	 Ling Ke Hebei Xiong’an Technology Co., Ltd.

(零氪河北雄安科技有限公司)
(seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative
	
	“YIKE SUBSIDIARY”
	
	 Yike Technology (Shanghai) Co., Ltd.

(医氪科技(上海)有限公司) (seal)

		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Legal Representative
	
	“WUXI SUBSIDIARY”
	
	 Shushu Yuji Medical Technology (Wuxi) Co., Ltd.

(树数愈疾医疗科技(无锡
)有限公司) (seal)

		
	By:	 	 /s/ Kaishan Chen

	Name:	 	Kaishan Chen (陈凯申)
	Title:	 	Legal Representative
	
	“Xiamen Subsidiary”
	
	 Ling Ke Technology (Xiamen) Co., Ltd.

(零氪科技(厦门)有限公司) (seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“Tianjin Subsidiary III”
	
	 Tianjin Linke Cloud Clinic Co., Ltd.

(天津邻客云诊所有限公司)
(seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“Tianjin Subsidiary III”
	
	 Tianjin Linke Cloud Clinic Co., Ltd

(天津邻客云诊所有限公司)
(seal)

		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Legal Representative

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“FOUNDERS” AND “FOUNDER ENTITIES”
	
	Tianze Zhang (张天泽)
		
	By:	 	 /s/ Tianze Zhang

	
	Digital Medical Technology Ltd.
		
	By:	 	 /s/ Tianze Zhang

	Name:	 	Tianze Zhang (张天泽)
	Title:	 	Director
	
	Liping Li (李丽平)
		
	By:	 	 /s/ Liping Li

	
	August Health Services Ltd.
		
	By:	 	 /s/ Liping Li

	Name:	 	Liping Li (李丽平)
	Title:	 	Director
	
	Ligang Luo (罗立刚)
		
	By:	 	 /s/ Ligang Luo

	
	Health BigData Technology Limited
		
	By:	 	 /s/ Ligang Luo

	Name:	 	Ligang Luo (罗立刚)
	Title:	 	Director

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
herein above first written. 
  

			
	“INVESTOR”
	
	Alibaba Health (Hong Kong) Technology Company Limited
		
	By:	 	 /s/ Lee Wai Yan Vivian

	Name:	 	Lee Wai Yan Vivian
	Title:	 	Director

 SIGNATURE PAGE TO 

SERIES D+ PREFERENCE SHARES SUBSCRIPTION AGREEMENT 

 Schedule A 

Definitions 

“Action” shall mean any action, suit, proceeding, arbitration, mediation, complaint, claim, charge or, to the Knowledge of
the Warrantors, investigation, in each case, before any court, arbitrator, mediator or governmental body. 
 “Affiliate”
shall mean, in respect of a Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls, is Controlled by, or is under common Control with, such Person, and (a) in the case of a natural Person, shall
include, without limitation, such Person’s spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, (b) in the case of an Investor, shall include any Person who holds shares as a nominee for the
Investor, and (c) in respect of an Investor, shall also include (i) any shareholder of the Investor, (ii) any entity or individual which has a direct and indirect interest in the Investor (including, if applicable, any general partner
or limited partner) or any fund manager thereof, (iii) any Person that directly or indirectly Controls, is Controlled by, under common Control with, or is managed or advised by the Investor or its fund manager, (iv) the relatives of any
individual referred to in (ii) above, and (v) any trust Controlled by or held for the benefit of such individuals. For the avoidance of doubt, no Investor shall be deemed to be an Affiliate of any Group Company. 

“Agreement” has the meaning given to that term in the introductory paragraph of this Agreement. 

“Ali Director” has the meaning given to that term in Section 6.1(f) of the Shareholders’ Agreement. 

“Ali Observer” has the meaning given to that term in Section 6.2 of the Shareholders’ Agreement. 

“Board” shall mean the board of directors of the Company. 

“Breach” has the meaning given to that term in Section 8.1 of this Agreement. 

“Business Cooperation Agreement” has the meaning given to that term in Section 5.15 of this Agreement. 

“Business Day” or “business day” shall mean any day that is not a Saturday, Sunday, legal holiday or a day
on which banks are required to be closed in the PRC, the Cayman Islands and Hong Kong. 
 “Closing” has the meaning given
to that term in Section 2.2(a) of this Agreement. 
 “Code” shall mean the United States Internal Revenue Code of
1986, as amended, and the rules and regulations promulgated by the United States Internal Revenue Service thereunder. 

“Company” has the meaning given to that term in introductory paragraph of this Agreement. 

 “Control”, with respect to any party, shall have the meaning given to that
term in Rule 405 under the Securities Act, and shall be deemed to exist for any party (a) when such party holds at least twenty percent (20%) of the outstanding voting securities of such third party and no other party owns a greater number
of outstanding voting securities of such third party, or (b) over other members of such party’s immediate family members, or (c) when such party possesses the power or authority, whether exercised or not, to direct the business,
management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, contractual arrangement or otherwise, or (d) such party possesses the beneficial ownership or power to direct the vote of more
than fifty percent (50%) of the votes entitled to be cast at a meeting of the members or shareholders of such Person, or power to control the composition of the board of directors or similar governing body of such Person. The terms
“Controlling” and “Controlled” have meanings correlative to the foregoing. 
 “Conversion
Shares” has the meaning given to that term in Section 2.1(a) of this Agreement. 
 “Disclosure Schedule”
shall mean the Disclosure Schedule attached as Exhibit A to this Agreement. 
 “Disqualification Event” has the
meaning given to that term in Section 3.33 of this Agreement. 
 “Domestic Company” has the meaning given to that term
in Section C of this Agreement. 
 “Domestic Company Holders” has the meaning given to that term in Section 7.10 of
this Agreement. 
 “Environmental Laws” shall mean any Law or other applicable requirement relating to (a) releases or
threatened release of Hazardous Substance; (b) pollution or protection of employee health or safety, public health or the environment; or (c) the manufacture, handling, transport, use, treatment, storage, or disposal of Hazardous
Substances. 
 “Equity Plan” shall mean the Company’s equity incentive plan approved by the Board on February 27,
2015, as amended from time to time, pursuant to which, 43,570,953 Ordinary Shares will have been reserved for issuance to officers, directors, employees, consultants or service providers of the Company immediately upon the Closing. 

“Financial Statements” has the meaning given to such term in Section 3.17 of this Agreement. 

“Financial Statements Date” has the meaning given to such term in Section 3.17 of this Agreement. 

“Founder(s)” has the meaning given to such term in introductory paragraph of this Agreement. 

“Founder Entity” has the meaning given to such term in introductory paragraph of this Agreement. 

 “Governmental Authority” shall mean (i) any nation, government,
federation, province or state or any other political subdivision thereof, or any national, provincial, municipal, local or foreign government or any entity exercising executive, legislative, judicial, regulatory or administrative functions of or
pertaining to government, including any Governmental Authority, agency, department, board, commission or instrumentality of the PRC, the Cayman Islands, Hong Kong or any other country, or any political subdivision thereof, any court, tribunal or
arbitrator, and any self-regulatory organization, (ii) any public international organization, (iii) any agency, division, bureau, department or other sector of any government, entity or organization described in the foregoing (i) or
(ii) of this definition, or (iv) any state-owned or state-controlled enterprise or other entity owned or controlled by any government, entity or organization described in (i), (ii) or (iii) of this definition. 

“Governmental Authorizations” has the meaning given to such term in Section 3.7 of this Agreement. 

“Governmental Order” shall mean any applicable order, ruling, decision, verdict, decree, writ, subpoena, mandate, precept,
command, directive, consent, approval, award, judgment, injunction or other similar determination or finding by, before or under the supervision of any Governmental Authority. 

“Group Companies” shall mean the Company and any other direct or indirect Subsidiary of the Company, including, but not
limited to, the WFOEs, the HK Entity, the PRC Entities, Houpu Subsidiary, Linke Subsidiary and Zhonghui Subsidiary, each of such Group Companies being referred to as a “Group Company” . 

“Group Company Intellectual Property” shall mean Intellectual Property that is necessary to the conduct of the Company’s
business as now conducted and as presently proposed to be conducted. 
 “Guangzhou Subsidiary” has the meaning given to
that term in Schedule C of this Agreement. 
 “Hebei Subsidiary” has the meaning given to that term in Schedule C of this
Agreement. 
 “Hazardous Substance” has the meaning given to such term in Section 3.28 of this Agreement. 

“HIPAA” shall mean Health Insurance Portability and Accountability Act promulgated by United States in 1996. 

“HK Entity” has the meaning given to that term in introductory paragraph of this Agreement. 

“HKIAC Rules” has the meaning given to that term in Section 9.16(b) of this Agreement. 

“Hong Kong” shall mean the Hong Kong Special Administrative Region of the PRC. 

“Houpu Restructuring Documents” shall mean the Exclusive Consulting and Service Agreement, Exclusive Call Option Agreement,
Equity Pledge Agreement and Shareholders Voting Rights Proxy Agreement entered into on September 4, 2020 by and among the WFOE I, the Domestic Company and the Houpu Subsidiary, each as may be amended from time to time. 

 “Houpu Subsidiary” shall mean Beijing Houpu Pharmaceutical Technology Co.,
Ltd. (北京厚普医药科技有限公司). 

“IFRS” shall mean the applicable International Financial Reporting Standards as published by the International Accounting
Standards Board from time to time. 
 “Indemnifiable Loss” and “Indemnifiable Losses” have the meanings
given to those terms in Section 8.1 of this Agreement. 
 “Indemnitee” has the meaning given to that term in
Section 8.1 of this Agreement. 
 “Intellectual Property” shall mean all registered or unregistered patents, patent
applications, trademarks, trademark applications, service marks, trade names, copyrights, trade secrets, licenses, domain names, mask works, information and proprietary rights and processes. 

“Investor” have the meanings given to those terms in introductory paragraph of this Agreement. 

“Investor Nominee” has the meaning given to that term in Section 7.10 of this Agreement. 

“Issuer Covered Person” has the meaning given to that term in Section 3.33 of this Agreement. 

“JV Restructuring Documents” shall mean the Exclusive Consulting and Service Agreement, Exclusive Call Option Agreement,
Equity Pledge Agreement, Shareholders Voting Rights Proxy Agreement and Loan Agreement entered into on September 4, 2020 by and among the WFOE I, each of Tianjin Jinnan Haihe River CBC IFOF Industrial Fund Partnership, L.P. (天津津南海河宽带智汇产业基金合伙企业(有限合伙)), Shanghai Cenova Kangze
Investment Center LL.P (上海千骥康泽投资中心(有限合伙)) and Suzhou Cenova Zekang Investment Center LL.P ( 苏州千骥泽康投资 中心 ( 有限合伙 )), CICC and Shenzhen Zhongshenxinchuang Investment Partnership (L.P.) (深圳中深新创股权投资合伙企业(有限 合伙)), and/or the JV Entity, each as may be amended from time to time. 

“Key Employees” shall mean the employees as listed in Exhibit B. 

“Key Founder” shall mean Tianze Zhang
(张天泽). 

“Knowledge” shall mean, with respect to a Person’s “Knowledge” about certain fact, the actual knowledge of
such Person (or the actual knowledge of such Person’s executive officers and other officers if such Person is an entity), and the knowledge which should have been acquired by such Person after making such due inquiry and exercising such due
diligence as a prudent business person would have made or exercised in the management of his/her/its business affairs, including due inquiry of those officers, directors, Key Employees and professional advisers (including attorneys, accountants and
consultants) of such Person and Affiliates thereof who would be reasonably expected to be aware of such fact, and where any statement in the representations and warranties hereunder is expressed to be given or made to a Person’s Knowledge, or
so far as a party is aware, or is qualified in some other manner having a similar effect, the statement shall be deemed to be supplemented by the additional statement that such Person has made such due inquiry and due diligence. 

 “Kuaima Subsidiary” has the meaning given to that term in Schedule C of
this Agreement. 
 “Law” or “Laws” shall mean any constitutional provision, statute or other law, rule,
regulation, official policy or interpretation of any Governmental Authority and any Governmental Order. 
 “Liability”
shall mean, with respect to any Person, any liability or obligation of such Person whether known or unknown, whether asserted or unasserted, whether determined, determinable or otherwise, whether absolute or contingent, whether accrued or unaccrued,
whether liquidated or unliquidated, whether directly incurred or consequential, whether due or to become due and whether or not required under U.S. GAAP to be accrued on the financial statements of such Person. 

“Lien” shall mean any lien, pledge, charge, claim, mortgage, security interest, restriction or other encumbrance of any sort.

 “Lingbo Subsidiary” has the meaning given to that term in Schedule C of this Agreement. 

“Lingce Subsidiary” has the meaning given to that term in Schedule C of this Agreement. 

“Linke Subsidiary” shall mean Linke Biological Technology Tianjin Co., Ltd. (邻客
生物科技(天津)
有限公司). 

“Material Adverse Effect” shall mean any (a) event, occurrence, fact, condition, change or development that has had,
has, or could reasonably be expected to have a material adverse effect on the business, properties, assets, employees, operations, results of operations, condition (financial or otherwise), prospects or Liabilities of the Group Companies taken as a
whole, (b) material impairment of the ability of any Warrantor to perform the material obligations of such Person hereunder or under any other Transaction Agreements, as applicable, or (c) material impairment of the validity or
enforceability of this Agreement or any other Transaction Agreements against any Group Company or Founder. 
 “Material
Agreement” has the meaning given to that term in Section 3.12(a) of this Agreement. 
 “Memorandum and Articles of
Association” has the meaning given to that term in Section 2.1(a) of this Agreement. 
 “Ningxia Subsidiary”
has the meaning given to that term in Schedule C of this Agreement. 
 “Ningxia Restructuring Document” shall mean the
Exclusive Consulting and Service Agreement, Exclusive Call Option Agreement, Equity Pledge Agreement and Shareholders Voting Rights Proxy Agreement entered into on September 4, 2020 by and among the WFOE I, the Domestic Company and Ningxia
Subsidiary, each as may be amended from time to time. 
 “Ordinary Shares” has the meaning given to that term in
Section 2.1(a) of this Agreement. 

 “Real World” has the meaning given to that term in Schedule C of this
Agreement. 
 “Person” shall mean any individual, corporation, partnership, trust, limited liability company, association
or other entity. 
 “Personal Data” shall mean any data or information in any media (including a browser or a device) that
is linked to the identity of a particular natural person and any other data or information that constitutes personal data or personal information under any applicable Law or any Group Company’s privacy policies. For the avoidance of doubt,
Personal Data includes a natural person’s combined first and last name, home address, telephone number, fax number, email address, medical record number or other Governmental Authority-issued identifier (including state identification number,
tax identification number, social security number, driver’s license number, or passport number), precise geolocation information of a natural person, biometric data, medical or health information, medical history, physical exams or test
results, medical images, credit card or other financial information (including bank account information), cookie identifiers associated with registration information, or any other browser- or device-specific number or identifier not controllable by
the end user, and web or mobile browsing or usage information that is linked to the foregoing. 
 “PRC” shall mean the
People’s Republic of China excluding, solely for the purposes of this Agreement, Hong Kong, the Macau Special Administrative Region and Taiwan. 

“PRC Announcement 7” shall mean Announcement No. 7 issued by the PRC State Administration of Taxation on
February 3, 2015, titled “Announcement on Certain Questions relating to the Enterprise Income Tax of Indirect Transfers of Assets by Non-Resident Enterprises (
关于非居民企业间接转让财产企业所得税若干问题的公告 )”, and any amendment, implementing rules, or official interpretation thereof or any replacement, successor or alternative legislation having the same subject matter thereof. 

“PRC Decree 1” shall mean Decree No.1 issued by the PRC Ministry of Commerce on January 9, 2021, titled “Measures
for Blocking Improper Extraterritorial Application of Foreign Laws and Measures ( 阻 断 外 国 法 律 与 措 施 不 当 域
外 适 用 办 法 )”, and any amendment, implementing rules, or official interpretation thereof or any replacement, successor or alternative legislation
having the same subject matter thereof. 
 “PRC Entities” shall have the meaning given to that term in the
introductory paragraph of this Agreement. 
 “Preference Director(s)” has the meaning given to that term in the
Shareholders’ Agreements. 
 “Preference Shares” shall mean the preference shares of the Company, US$0.00008 nominal
or par value per share. 
 “Process” or “Processing” shall mean the receipt, acquisition, collection,
recording, compilation, organization, structuring, storage, adaptation, alternation, retrieval, use, disclosure by transmission, dissemination or otherwise making available, erasure, destruction, restriction, and other forms of exploitation of
Personal Data. 
 “Prohibited Payment” has the meaning given to that term in Section 3.24 of this Agreement. 

 “Proprietary Rights” shall mean any and all worldwide, international, PRC,
or foreign patents, all patent rights and all applications therefore and all reissues, re-examinations, continuations, continuations-in-part, divisions, and patent term extensions thereof, inventions (whether patentable or not), discoveries,
improvements, concepts, innovations, industrial models, registered and unregistered copyrights, copyright registrations and applications, author’s rights, works of authorship, URLs, web sites, web pages and any part thereof, technical
information, know-how, trade secrets, drawings, designs, design protocols, specifications for parts and devices, quality assurance and control procedures, design tools, manuals, research data concerning historic and current research and development
efforts, including the results of successful and unsuccessful designs, databases and proprietary data, proprietary processes, proprietary rights, technology, engineering, discoveries, formulae, algorithms, operational procedures, trade names, trade
dress, trademarks, domain names, service marks, mask works, and registrations and applications therefore, the goodwill of the business symbolized or represented by the foregoing, customer lists and other proprietary information and common law
rights. 
 “Subscription Price” has the meaning given to that term in Section 2.1(b) of this Agreement. 

“Subscribed Shares” has the meaning given to that term in Section 2.1(a) of this Agreement. 

“Qualified Medical Record Ratio” has the meaning given to that term in Section 7.11 of this Agreement. 

“Qualified IPO” has the meaning given to that term in the Shareholders’ Agreements. 

“Real World Restructuring Documents” shall mean the Exclusive Consulting and Service Agreement, Exclusive Call Option
Agreement, Equity Pledge Agreement and Shareholders Voting Rights Proxy Agreement entered into on September 4, 2020 by and among the WFOE I, the Domestic Company and Real World, each as may be amended from time to time. 

“Regulations” has the meaning given to that term in Section 3.21 of this Agreement. 

“Restructuring Documents” shall mean (i) the Exclusive Consulting and Service Agreement, Exclusive Call Option
Agreement, Equity Pledge Agreement, Shareholders Voting Rights Proxy Agreement and Spousal Consent entered into on February 27, 2015 by and among the WFOE I, the Domestic Company and/or the shareholders of the Domestic Company or the spouse of
certain shareholder of the Domestic Company (as applicable), each as may be amended from time to time, (ii) the Tianjin Restructuring Documents, (iii) the JV Restructuring Documents, (iv) Houpu Restructuring Documents,
(v) Ningxia Restructuring Documents, and (vi) Real World Restructuring Documents. 
 “RMB” shall mean Renminbi,
the lawful currency of the PRC. 
 “SAFE” has the meaning given to that term in Section 3.4(f) of this Agreement. 

“SEC” shall mean the U.S. Securities and Exchange Commission. 

“Securities Act” shall mean the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated by the SEC
thereunder. 

 “Security Breach” shall mean any (i) unauthorized acquisition of,
access to, loss of, or misuse (by any means) of Personal Data or sensitive data; (ii) unauthorized or unlawful Processing, sale, or rental of Personal Data or sensitive data; or (iii) other act or omission that compromises the security,
integrity, or confidentiality of Personal Data or sensitive data, in each case of (i) to (iii), with respect to such data maintained by a Group Company or by any third party on behalf of a Group Company. 

“Series A Preference Shares” shall mean the Series A Preference Shares in the share capital of the Company, nominal or par
value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 
 “Series B Preference
Shares” shall mean the Series B Preference Shares in the share capital of the Company, nominal or par value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 

“Series C-1 Preference Shares” shall mean the Series C-1 Preference Shares in the share capital of the Company, nominal or
par value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 
 “Series C-2
Preference Shares” shall mean the Series C-2 Preference Shares in the share capital of the Company, nominal or par value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 

“Series D Preference Shares” shall mean the Series D Preference Shares in the share capital of the Company, nominal or par
value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 
 “Series D Purchase
Agreement” shall mean the Series D Preference Shares Agreement by and among the Company, the HK Entity, the WFOE I, the Domestic Company and certain other parties thereto dated May 18, 2018. 

“Series D+ Preference Shares” shall mean the Series D+ Preference Shares in the share capital of the Company, nominal or par
value of US$0.00008 per share, having the rights set forth in the Memorandum and Articles of Association. 
 “Series D+ Purchase
Agreement I” shall mean the Option and Series D+ Preference Shares Purchase Agreement by and among the Company, the HK Entity, the WFOE, the Domestic Company and certain other parties thereto dated August 21, 2020. 

“Shareholders’ Agreement” shall mean the fifth amended and restated shareholders’ agreement among the Group
Companies, the Investor, the Founders and certain other members of the Company to be executed by the parties upon the Closing in the form as attached to this Agreement as Exhibit C. 

“Share Sale and Purchase Agreement” shall mean the share sale and purchase agreement entered into by and among the Investor,
the Company, August Health Services Ltd., Health BigData Technology Limited and Peng Cloud Investments Limited on February 10, 2021. 

“Statute” has the meaning given to that term in Section 3.1(a) of this Agreement. 

 “Subsidiary” or “subsidiary” shall mean, with respect to
any subject entity (the “subject entity”), (i) any company, partnership or other entity (x) more than 50% of whose shares or other interests entitled to vote in the election of directors or (y) more than a 50%
interest in the profits or capital of such entity are owned or Controlled, directly or indirectly, by the subject entity or through one (1) or more Subsidiaries of the subject entity, (ii) any entity whose assets, or portions thereof, are
consolidated with the net earnings of the subject entity and are recorded on the books of the subject entity for financial reporting purposes in accordance with IFRS or U.S. GAAP, or (iii) any entity with respect to which the subject entity has
the power to otherwise direct the business and policies of that entity directly or indirectly through another subsidiary. For the avoidance of doubt, the Subsidiaries of the Company shall include the WFOEs, the HK Entity, the PRC Entities and any
Subsidiary that the Company may establish or acquire from time to time. 
 “Systems” shall mean the applications,
databases, clouds, software, hardware, firmware, networks, switches, endpoints, platforms, servers, storage space, interfaces, websites and related information technology platforms, and all electronic connections between and among them, owned,
operated or used by the Group Company or the business as of the date of this Agreement, including all such Systems that Process data. 

“Tax” or “Taxes” shall mean (i) in the PRC: (A) any national, provincial, municipal, or local
taxes, charges, fees, levies, or other assessments, including, without limitation, all net income (including enterprise income tax and individual income withholding tax), turnover (including value-added tax, business tax, and consumption tax),
resource (including urban and township land use tax), special purpose (including land value-added tax, urban maintenance and construction tax, and additional education fees), property (including urban real estate tax and land use fees),
documentation (including stamp duty and deed tax), filing, recording, social insurance (including pension, medical, unemployment, housing, and other social insurance withholding), tariffs (including import duty and import value-added tax), and
estimated and provisional taxes, charges, fees, levies, or other assessments of any kind whatsoever, (B) all interest, penalties (administrative, civil or criminal), late payment surcharge or additional amounts imposed by any Governmental
Authority in connection with any item described in clause (A) above, and (C) any form of transferee liability imposed by any Governmental Authority in connection with any item described in clauses (A) and (B) above, and
(ii) in any jurisdiction other than the PRC: all similar liabilities as described in clause (i) above. 
 “Tax
Return” shall mean any return, report or statement showing Taxes, used to pay Taxes, or required to be filed with respect to any Tax (including any elections, declarations, schedules or attachments thereto, and any amendment thereof),
including any information return, claim for refund, amended return or declaration of estimated or provisional Tax. 
 “Tianjin
Restructuring Documents” shall mean the Exclusive Consulting and Service Agreement, Exclusive Call Option Agreement, Shareholders Voting Rights Proxy Agreement entered into on March 18, 2017 by and among the WFOE I, the Tianjin
Subsidiary I, the Tianjin Subsidiary II and the Domestic Company, each as may be amended from time to time, and the Equity Pledge Agreement and Loan Agreement entered into on September 4, 2020 by and among the WFOE I, the Domestic Company
and/or Tianjin Subsidiary I, each as may be amended from time to time 
 “Tianjin Subsidiary I” has the meaning given to
that term in Schedule C of this Agreement. 
 “Tianjin Subsidiary II” has the meaning given to that term in Schedule C of
this Agreement. 

 “Tianjin Subsidiary III” has the meaning given to that term in Schedule C
of this Agreement. 
 “Transaction Agreements” shall mean this Agreement, the Shareholders’ Agreement, the Memorandum
and Articles of Association, the Share Sale and Purchase Agreement, the Indemnification Agreement and any other document, certificate, and agreement delivered in connection with the transactions contemplated hereby and thereby, but, for avoidance of
doubt, excluding the Business Cooperation Agreement. 
 “U.S.” or “United States” shall mean the United
States of America. 
 “U.S. GAAP” shall mean the accounting principles generally accepted in the United States. 

“Warrantors” shall mean the Company, the WFOEs, the HK Entity, the PRC Entities, the Founders and the Founder Entities, each
of such Warrantors being referred to as a “Warrantor”. 
 “WFOE I” has the meaning given to that term in
introductory paragraph of this Agreement. 
 “WFOE II” has the meaning given to that term in introductory paragraph of this
Agreement. 
 “WFOE(s)” have the meaning given to that term in introductory paragraph of this Agreement. 

“WFOE Capital Injection Amount” has the meaning given to that term in Section 7.16 of this Agreement. 

“Wuxi Subsidiary” has the meaning given to that term in Schedule C of this Agreement. 

“Xiamen Subsidiary” has the meaning given to that term in Schedule C of this Agreement. 

“Yike Subsidiary” has the meaning given to that term in Schedule C of this Agreement. 

“Yingke Subsidiary” shall mean Beijing Yingye Shengjie Intelligent Technology Center (Limited Partnership) (北京盈氪盛捷智能科技中心(有限合伙)). 

“Zhonghe Subsidiary” shall mean Tianjin Houpu Zhonghe Pharmaceutical Technology Co., Ltd. (天津厚普众合医药科技有限公司). 

“Zhonghui Subsidiary” shall mean Beijing Houpzhonghui Pharmaceutical Technology Co., Ltd. (北京厚普众惠医药科技有限公司). 

 Schedule B 

Schedule of Investor 
  

											
	 Name of Investor
	  	Number of
Shares	 	  	Subscription
Price	 	  	Series of
Preference Shares
	 Alibaba Health (Hong Kong)

Technology Company Limited
	  	 	21,669,131	 	  	US$	59,313,696	 	  	Series D+
Preference Shares
		  	  
	  
	 	  	  
	  
	 	  	
	 TOTAL:
	  	 	21,669,131	 	  	US$	59,313,696	 	  	—  
		  	  
	  
	 	  	  
	  
	 	  	

 Schedule C 

Schedule of PRC Entities 
  

					
	 No.
	  	 Name and Address of PRC Entities
	  	 United Social Credit Code

(统一社会信用代码)

	1.	  	Ling Ke Technology (Beijing) Co., Ltd. (零氪科技 (北京)有限公司)
(the “Domestic Company”)	  	91110108327142377N
			
	2.	  	Ling Ke Technology (Tianjin) Co., Ltd. (零氪科技 (天津)有限公司)
(the “Tianjin Subsidiary I”)	  	91120118MA05L2NQ0R
			
	3.	  	Ling Ke Medical Intelligent Technology (Guangzhou) Co., Ltd. (零氪医疗智能科技(广州)有 限公司) (the “Guangzhou Subsidiary”)	  	91440101MA59U26H0Y
			
	4.	  	Yinchuan Ling Ke Medical Internet Co., Ltd. (银川 零氪互联网医院有限公司) (the “Ningxia
Subsidiary”)	  	91640100MA76D8QG43
			
	5.	  	Ling Ke Medical Technology (Tianjin) Co., Ltd. (零
氪医疗科技(天津)有限公司) (the “JV Entity”)	  	91120000MA072MGB6P
			
	6.	  	Beijing Kuaima Hulian Technology Co., Ltd. (北京 快马互联科技有限公司) (“Kuaima Subsidiary”)	  	91110107330362178B
			
	7.	  	Real World Medical Technology (Beijing) Co., Ltd.
(瑞尔沃德医药科技(北京)有限公司) (“Real
World”)	  	91110108MA00CB0X2T
			
	8.	  	Lingbo (Beijing) Medical Technology Co., Ltd. (领
博(北京)医疗科技有限公司) (the “Lingbo Subsidiary”)	  	91110105344281707N
			
	9.	  	Beijing Lingce Smart Technology Center (Limited Partnership)
(北京领策智能科技中心(有限合伙)) (the “Lingce Subsidiary”)	  	91110108MA01AAUM0H
			
	10.	  	Ling Ke Hebei Xiong’an Technology Co., Ltd. (零 氪河北雄安科技有限公司) (the “Hebei
Subsidiary”)	  	91130629MA0D6FCA0L

					
	11.	  	Yike Technology (Shanghai) Co., Ltd. (医氪科技(上 海)有限公司) (the
“Yike Subsidiary”)	  	91310115MA1K470R9A
			
	12.	  	Shushu Yuji Medical Technology (Wuxi) Co., Ltd.
(树数愈疾医疗科技(无锡)有限公司) (the “Wuxi
Subsidiary”)	  	91320214MA23NRYL0Q
			
	13.	  	Ling Ke Intelligent Medical Technology (Tianjin) Co., Ltd. (零氪智慧医疗科技(天津)有限公司) (the “Tianjin Subsidiary II”)	  	91120112MA077E3332
			
	14.	  	Ling Ke Technology (Xiamen) Co., Ltd. (零氪科技 (厦门)有限公司)
(the “Xiamen Subsidiary”)	  	91350200MA34B5RF4R
			
	15.	  	Tianjin Linke Cloud Clinic Co., Ltd (天津邻客云诊 所有限公司) (the “Tianjin Subsidiary III”)	  	91120116MA077YRKXD

 Schedule D 

Schedule of Founders 
  

			
	 Founders
	  	 Founder Entities

	Tianze Zhang (张天泽)	  	 Digital Medical Technology Ltd.,
 Office of
Sertus Incorporations (BVI) Limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands.

	Liping Li (李丽平)	  	 August Health Services Ltd.,
 Office of
Sertus Incorporations (BVI) Limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands.

	Ligang Luo (罗立刚)	  	 Health BigData Technology Limited,
 Office of
Sertus Incorporations (BVI) Limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands.

	 TOTAL:
	  	-

 Schedule E 

Capitalization Table of the Company 
  

																	
	 Shareholder
	  	Immediately Prior to
the Closing	 	 	Immediately after the
Closing	 
	  	Number of
Shares	 	  	Percentage	 	 	Number of
Shares	 	  	Percentage	 
	 Ordinary Shares
	  				  				 				  			
	 Tianze Zhang (张天泽) (through Digital
Medical Technology Ltd.)
	  	 	75,000,000	 	  	 	22.9216	% 	 	 	75,000,000	 	  	 	21.4978	% 
	 Liping Li (李丽平) (through August Health
Services Ltd.)
	  	 	12,500,000	 	  	 	3.8203	% 	 	 	11,000,000	 	  	 	3.1530	% 
	 Ligang Luo (罗立刚) (through Health BigData
Technology Limited)
	  	 	10,000,000	 	  	 	3.0563	% 	 	 	9,000,000	 	  	 	2.5797	% 
	 Peng Tang (汤鹏) (through Peng Cloud Investments
Limited)
	  	 	2,158,613	 	  	 	0.6597	% 	 	 	/	 	  	 	/	 
	 INDEX Capital International Limited
	  	 	966,387	 	  	 	0.2953	% 	 	 	966,387	 	  	 	0.2770	% 
	 Option Pool (reserved)
	  	 	43,570,953	 	  	 	13.3161	% 	 	 	43,570,953	 	  	 	12.4890	% 
					
	 Series A Preference Shares
	  				  				 				  			
	 New Enterprise Associates 15, L.P.
	  	 	16,455,881	 	  	 	5.0292	% 	 	 	16,455,881	 	  	 	4.7169	% 
	 NEA Ventures 2015, L.P.
	  	 	117,650	 	  	 	0.0360	% 	 	 	117,650	 	  	 	0.0337	% 
	 Long Hill Capital Venture Partners 1, L.P.
	  	 	5,485,294	 	  	 	1.6764	% 	 	 	5,485,294	 	  	 	1.5723	% 
					
	 Series B Preference Shares
	  				  				 				  			
	 New Enterprise Associates 15, L.P.
	  	 	7,878,151	 	  	 	2.4077	% 	 	 	7,878,151	 	  	 	2.2582	% 
	 China Broadband Capital Partners III, L.P.
	  	 	21,008,404	 	  	 	6.4206	% 	 	 	21,008,404	 	  	 	6.0218	% 
	 ABG II-SO2 Limited
	  	 	8,403,361	 	  	 	2.5682	% 	 	 	8,403,361	 	  	 	2.4087	% 
	 Shanghai Cenova Xinghe Venture Capital Center, L.P.
	  	 	6,302,521	 	  	 	1.9262	% 	 	 	6,302,521	 	  	 	1.8065	% 
	 Long Hill Capital Venture Partners 1, L.P.
	  	 	2,626,051	 	  	 	0.8026	% 	 	 	2,626,051	 	  	 	0.7527	% 
					
	 Series C-1 Preference Shares
	  				  				 				  			
	 ABG II-SO2 Limited
	  	 	2,899,160	 	  	 	0.8860	% 	 	 	2,899,160	 	  	 	0.8310	% 
					
	 Series C-2 Preference Shares
	  				  				 				  			

																	
	 Esta Investments Pte Ltd
	  	 	23,193,278	 	  	 	7.0883	% 	 	 	23,193,278	 	  	 	6.6481	% 
	 New Enterprise Associates 15, L.P.
	  	 	2,635,137	 	  	 	0.8054	% 	 	 	2,635,137	 	  	 	0.7553	% 
	 China Broadband Capital Partners III, L.P.
	  	 	3,676,471	 	  	 	1.1236	% 	 	 	3,676,471	 	  	 	1.0538	% 
	 Long Hill Capital Venture Partners 1, L.P.
	  	 	1,419,485	 	  	 	0.4338	% 	 	 	1,419,485	 	  	 	0.4069	% 
	 Ningbo Huiqiao Hongjia Equity Investment Limited
Partnership
(宁 波汇桥弘甲股权投资合伙企业(有 限合伙)) (reserved
and deemed exercied)
	  	 	4,474,141	 	  	 	1.3674	% 	 	 	4,474,141	 	  	 	1.2825	% 
					
	 Series D Preference Shares
	  				  				 				  			
	 Lifetech Company Ltd
	  	 	19,699,210	 	  	 	6.0205	% 	 	 	19,699,210	 	  	 	5.6465	% 
	 Beijing Freesia Management Consulting Corporation
(北京芳盛 管理咨询有限责任公司)
	  	 	13,789,447	 	  	 	4.2143	% 	 	 	13,789,447	 	  	 	3.9526	% 
	 Esta Investments Pte Ltd
	  	 	7,225,565	 	  	 	2.2083	% 	 	 	7,225,565	 	  	 	2.0711	% 
	 China Broadband Capital Partners III, L.P.
	  	 	3,939,842	 	  	 	1.2041	% 	 	 	3,939,842	 	  	 	1.1293	% 
	 Long Hill Capital Venture Partners 1, L.P.
	  	 	1,221,351	 	  	 	0.3733	% 	 	 	1,221,351	 	  	 	0.3501	% 
	 New Enterprise Associates 15, L.P.
	  	 	3,471,105	 	  	 	1.0608	% 	 	 	3,471,105	 	  	 	0.9949	% 
	 Ningbo Huiqiao Hongbo Equity Investment Limited
Partnership
(宁 波汇桥弘博股权投资合伙企业(有 限合伙)) (reserved
and deemed exercied)
	  	 	1,871,425	 	  	 	0.5719	% 	 	 	1,871,425	 	  	 	0.5364	% 
					
	 Series D+ Preference Shares
	  				  				 				  			
	 HL Plus Holding I Limited
	  	 	4,727,810	 	  	 	1.4449	% 	 	 	4,727,810	 	  	 	1.3552	% 
	 New Enterprise Associates 15, L.P.
	  	 	1,181,953	 	  	 	0.3612	% 	 	 	1,181,953	 	  	 	0.3388	% 
	 Tianjin Jinnan Haihe River CBC IFOF Industrial Fund Partnership, L.P.
(天津津南海河宽带智汇产业 基金合伙企业(有限合伙)) (reserved and deemed
exercied)
	  	 	5,909,763	 	  	 	1.8061	% 	 	 	5,909,763	 	  	 	1.6940	% 
	 Esta Investments Pte Ltd
	  	 	5,909,763	 	  	 	1.8061	% 	 	 	5,909,763	 	  	 	1.6940	% 
	 Shanghai Cenova Kangze Investment Center LL.P
(上海千 骥康泽投资中心(有限合伙))
(reserved and deemed exercied)
	  	 	896,255	 	  	 	0.2739	% 	 	 	896,255	 	  	 	0.2569	% 
	 Suzhou Cenova Zekang Investment Center LL.P
(苏州千骥泽康投资 中心(有限合伙))
(reserved and deemed
exercied)
	  	 	1,073,666	 	  	 	0.3281	% 	 	 	1,073,666	 	  	 	0.3078	% 

																	
	 Shenzhen Zhongshenxinchuang Investment Partnership
(L.P.)
(深圳 中深新创股权投资合伙企业(有 限合伙)) (reserved and deemed
exercied)
	  	 	2,757,889	 	  	 	0.8429	% 	 	 	2,757,889	 	  	 	0.7905	% 
	 CICC Biomedical Fund L.P. (中金
启德(厦门)创新生物医药股权 投资基金合伙企业(有限合伙)) (reserved and
deemed exercied)
	  	 	2,757,889	 	  	 	0.8429	% 	 	 	2,757,889	 	  	 	0.7905	% 
	 Alibaba Health (Hong Kong) Technology Company Limited
(purchased pursuant to this
Agreement)
	  	 	/	 	  	 	/	 	 	 	21,669,131	 	  	 	6.2112	% 
	 Alibaba Health (Hong Kong) Technology Company Limited
(purchased pursuant to the Share Sale and
Purchase Agreement)
	  	 	/	 	  	 	/	 	 	 	4,658,613	 	  	 	1.3353	% 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 
	 Total Shares:
	  	 	327,203,871	 	  	 	100.0000	% 	 	 	348,873,002	 	  	 	100.0000	% 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 

 Schedule F 

ADDRESSES FOR NOTICE 
 If to the
Warrantors: 
  

			
	Address:	  	11th Floor, Building A, Sinosteel International Plaza, 8 Haidian
		  	Street, Haidian District, Beijing, China(北京市海淀区海淀大街
		  	8号中钢国际广场A座11层
	Tel:	  	(86) 186-0109-9880
	Attention:	  	Tianze Zhang (张天泽)
	Email:	  	tony@linkdoc.com

 If to the Investor: 
  

			
	Address:	  	17/F, Block B, Greenland Center, Wangjing Hongtai East Street,
Chaoyang District, Beijing
(北京朝阳区望京宏泰东街绿地中 心 B 座 17
层)
	Postal code:	  	100102
	Attention:	  	legal department of Ali Health
	Email:	  	alihealth-notice@alibaba-inc.com

 Exhibit A 

Disclosure Schedule 

 Exhibit B 

Key Employees 

 Exhibit C 

Shareholders’ Agreement 

 Exhibit D 

Sixth Amended and Restated Memorandum and Articles of Association 

 Exhibit E 

Form of Indemnification Agreement 

 Exhibit F 

Business Cooperation Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]